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1 Introduction  1 
1 Introduction 
The balance of signaling pathways is essential for maintaining cellular homeostasis. Signal 
transmission via ligands circulating through the cell surface receptors triggers specific signal 
transduction pathways. Inappropriate activation or inhibition of cell signaling pathways have 
been implicated in the development of numerous human diseases.  
Among others, the transforming growth factor (TGFβ) pathway regulates a variety of cellular 
processes and is playing a pivotal role in the maintenance of homeostasis of most human tissues 
(Gordon and Blobe 2008). 
 
1.1 TGFβ ligand family  
TGFβ is a multifunctional cytokine, which represents a large superfamily, composed of more 
than 30 related proteins in mammals, including activins and inhibins, isoforms of TGFβs (1-3), 
nodal, myostatin, bone morphogenetic proteins (BMPs), anti-Müllerian hormone (AMH) and 
growth and differentiation factors (GDFs). The members of the family are dimeric proteins and 
share common sequence and structural features (Kubiczkova et al. 2012, Leask and Abraham 
2004, Massague 1990, Ruiz-Ortega et al. 2007). It was shown that not only increased or 
decreased production of TGFβ but also mutations in the genes for TGFβ and its receptors are 
associated with various diseases and disorders, like cancer (Massague 2008, Massague et al. 
2000), fibrotic disease of the kidney (August and Suthanthiran 2003, Bottinger and Bitzer 
2002), liver and lungs (Leask and Abraham 2004, Verrecchia and Mauviel 2007, Wells 2000), 
atherosclerosis (Grainger 2007, Lutgens et al. 2002) hereditary hemorrhagic telangiectasia 
(HHT), immunomodulation (Tang et al. 2003). 
Of the three known isoforms of TGFβ (TGFβ1, TGFβ2 and TGFβ3), TGFβ1 is the most 
abundant and ubiquitously expressed protein (Kubiczkova et al. 2012).  
TGFβ1 is implicated in many physiological and pathological processes. It is a key player in cell 
proliferation, differentiation, apoptosis, adhesion, and migration. Furthermore, TGFβ1 induces 
production of extracellular matrix (ECM) proteins and mediates fibrotic response (Dennler et 
al. 2002, Leask and Abraham 2004, Shi and Massague 2003).  
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1.2 Medical relevance of TGFβ1 
 
1.2.1 Role of TGFβ1 in fibrosis 
Trauma or insult activates immune cells resulting in a chronic inflammatory response that 
initiates and perpetuates fibrosis. TGFβ1 is a major orchestrator in tissue repair, wound healing 
and fibrotic development in many organs including lungs, heart, liver, kidney, brain, pancreas, 
skin, bone, muscle (Branton and Kopp 1999, Hold et al. 2009). Depending on the disease phase, 
TGFβ1 plays an exacerbating or ameliorating role (Pohlers et al. 2009). Acute und limited tissue 
damage (like wound or inflammation) increases liberation and activation of TGFβ1 that attracts 
neutrophils, macrophages and fibroblasts, which in turn liberate more TGFβ1 (Leask and 
Abraham 2004). TGFβ1 induces the expression of ECM proteins, particularly collagen I, by 
stimulating gene transcription of COL1A1 and COL1A2 that encode polypeptides forming 
type  I collagen. Simultaneously, TGFβ1 inhibits the metalloproteinases (TIMP) and matrix 
metalloproteinases (MMP), which degrade ECM. Transient activity of TGFβ1 leads to tissue 
repair and remodeling. In case of repeated injury and in a number of fibrotic diseases, persistent 
overproduction of TGFβ1 leads to progressive production and deposition of ECM and tissue 
fibrosis, that results in organ failure (Border and Noble 1994, Hold et al. 2009).  
 
1.2.2  Role of TGFβ1 in atherosclerosis 
Numerous studies elucidated the role of TGFβ1 in the maintenance of the normal blood vessel 
wall architecture (Grainger 2007, Mallat and Tedgui 2002). TGFβ1 was found to be an 
important modulator of fibrosis and immuno-inflammatory balance, which is critical in 
maintenance of plaque stability in atherosclerosis (Mallat and Tedgui 2002). An anti-
atherogenic role of TGFβ1 signaling is due to inhibition of T cells resulting in anti-
inflammatory effects (Hansson and Robertson 2004). Consistent with this hypothesis, reduced 
levels of circulating TGFβ1 in the plasma of patients with atherosclerosis were found (Toma 
and McCaffrey 2012). Due to its pro-fibrotic effects, TGFβ1 overexpression leads, on the one 
hand, to stabilization of atherosclerotic plaques (Mallat and Tedgui 2002), but also favors 
extracellular matrix growth and thus further development of the plaque (Mehta and Attramadal 
2007). Inhibition of TGFβ1 signaling pathway by Apolipoprotein A, a homologue of 
plasminogen, promoted the proliferation of vascular smooth muscle cells. Additionally, 
treatment with neutralizing anti-TGFβ antibodies led to increased vascular inflammation and 
increased plaque instability (Grainger et al. 1994, Lutgens et al. 2002, Mallat et al. 2001). 
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1.2.3 Role of TGFβ1 in renal disease 
A number of studies showed a role of TGFβ1 as a key modulator in the development and 
progression of renal fibrosis and inflammation in chronic renal disease (Border and Noble 1994, 
Bottinger and Bitzer 2002, Lan and Chung 2012). Many renal cells produce TGFβ1 and are 
sensitive to its effects. Mesangial cells were suggested to be one of the major sources of TGFβ1 
secretion as well as to be involved in TGFβ1 activation in the affected glomeruli. In various 
renal disorders, such as glomerulonephritis and diabetic nephropathy TGFβ1 is upregulated in 
the glomeruli. TGFβ1 induces expression of ECM proteins (collagens type I, III, IV; laminin; 
fibronectin and heparin sulphate proteoglycans), inhibits matrix degradation by reducing the 
activity of ECM-degrading proteinases and upregulates synthesis of proteinase inhibitors, 
leading to excessive matrix accumulation. Moreover, by upregulating plasminogen activator 
inhibitor production, TGFβ1 counteracts the activity of matrix-degrading metalloproteinases 
(Kitamura and Suto 1997, Loeffler and Wolf 2014). Friedman and colleagues demonstrated 
overproduction of local TGFβ1 and concomitant accumulation of ECM in both acute and 
chronic renal diseases (Border and Noble 1993). Furthermore, in patients with different renal 
diseases increased urine TGFβ1 levels were observed together with increased intestitial fibrosis 
and mesangial matrix (Murakami et al. 1997). As TGFβ1 is overexpressed in almost all renal 
diseases, TGFβ1 suppressing treatment with anti-TGFβ antibodies might inhibit excessive 
ECM accumulation and amelioration of renal fibrosis in chronic kidney disease as well as 
possible prevention of early glomerular lesions (Fukasawa et al. 2004). Moreover, Trachtman 
and colleagues first administered single-dose fresolimumab, a human monoclonal anti-TGFβ 
antibody, in treatment-resistant primary focal segmental glomerulosclerosis (FSGS). This phase 
I clinical trial showed that fresolimumab was well tolerated in patients with FSGS. Thereby, 
for assessment of this agent’s efficacy additional evaluation in larger studies is required 
(Trachtman et al. 2011).  
 
1.2.4 Role of TGFβ1 in liver disease 
Among the various cytokines, TGFβ1 secreted from both paracrine and autocrine sources is a 
central modulator of fibrogenic remodeling in the liver (Bottinger and Bitzer 2002, Lan and 
Chung 2012). In different stages of liver disease development and progression, TGFβ1 has 
either profibrotic or antifibrotic roles (Rosenstein 2011). Once the liver is injured, TGFβ1 
stimulates proliferation of hepatocytes and induces hepatic stellate cells (HCC) activation into 
myofibroblasts (Bottinger and Bitzer 2002, Lan and Chung 2012, Pohlers et al. 2009). Activated 
myofibrobalsts orchestrates production of ECM proteins like fibronectin; collagen type I, III 
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and IV, elastin, biglycan in normal and fibrotic liver (Kitamura and Suto 1997, Lan and Chung 
2012). Repeated injury and/or persistent inflammation in liver, caused by various risk factors 
including hepatitis B and C virus infection, alcoholic liver disease, fatty liver disease, promotes 
liver fibrosis (Pohlers et al. 2009). Liver fibrosis is characterized by excessive deposition of 
ECM that distorts the architecture of the liver by forming fibrotic scars leading to organ 
dysfunction. Furthermore, subsequent development of nodules of regenerating hepatocytes 
leads to liver cirrhosis (Murakami et al. 1997, Parsons et al. 2007). Moreover, hepatocyte 
tolerance to TGFβ1 changes during cirrhosis development. The cells appear to become resistant 
to TGFβ1-induced apoptosis suggesting the presence of pre-neoplastic changes in the cirrhotic 
liver (Wolff et al. 2011). During liver disease progression, chronic inflammation changes the 
tumor-suppressive role of TGFβ1 to fibrinogenetic, therefore accelerating liver fibrosis 
(Arestrom et al. 2012). With progression of fibrinogenesis the expression of integrin is elevated. 
Integrin is a major cell surface receptor for ECM that interacts with TGFβ1 and other ECM 
proteins and is able to modulate signal transduction cascade (Pohlers et al. 2009). Further, a 
shift of TGFβ1-induced pattern of phosphorylated Smads and subsequently altered 
transcriptional activities were shown (Arestrom et al. 2012). Nagata and colleagues indicated 
that in rat administration of JNK kinases, which phosphorylate linker regions of Smads, 
inhibited progression of hepatocellular carcinoma (Nagata et al. 2009). 
 
1.2.5 Role of TGFβ1 in cancer  
TGFβ1 regulates cellular proliferation, differentiation, and apoptosis. Dependent on the cell 
type, growth conditions and the presence of other growth factors, TGFβ1 plays multiple 
functions during normal development or in pathological conditions (Hyytiainen et al. 2004, 
Jakowlew 2006). In contrast to healthy tissues with a constant liberation of TGFβ1, injured 
tissues start to express TGFβ1 in high amounts to prevent inflammation (Massague 2008). 
During tumorigenesis, TGFβ1 has a dual nature, acting as a tumor suppressor in early stages of 
cancer, and switching the role to a tumor promoter at later stages (Drabsch and ten Dijke 2011). 
TGFβ1 exerts tumor suppressive effect by inhibiting cell proliferation and inducing apoptosis 
through arresting the cell cycle in G1 phase. It stimulates the production of the cyclin-dependent 
kinase (CDK) inhibitor p15 and thus inhibits the function of CDKs like c - Myc, which is the 
gene that regulates progression through the cell cycle (Blobe et al. 2000, Kubiczkova et al. 
2012). 
Malignant tissue often features high levels of active TGFβ1 released from the stored latent 
complex by increased protease expression, plasmin generation and degradation of extracellular 
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matrix. During tumor development, malignant cells become resistant to growth inhibition by 
TGFβ through mutations and/or inactivation of TGFβ1 signaling components (such as TGFβ 
receptors or SMAD 2/4 transcriptional factors). TGFβ1 now appears as a pro-oncogenic factor 
and promotes tumor progression and metastasis. It increases invasiveness of the tumor and 
affects the tumor micro-environment, which induces formation of new blood vessels for 
delivery of nutrients and oxygen to the cancer cells (Derynck et al. 2001). Numerous studies 
have shown associations between an inactivated TGFβ signaling pathway and increased tumor 
spreading and metastasis in breast, pancreatic, colon, intestinal cancers (Border and Noble 
1995, Branton and Kopp 1999, Kubiczkova et al. 2012).  
 
1.2.6 TGFβ signaling and radiotoxicity  
Radiotherapy alone or in combination with chemotherapy is a standard treatment widely applied 
for patients in oncology. Whenever treatment modalities are intensified many patients suffer 
from acute toxicity and long-term side effects (Schirmer et al. 2012). Patients receiving same 
therapeutic regimens exhibit a broad range of response and side effects. In severe cases, the 
latter can limit a definitive cure, e.g. if dose reduction or therapy stop is required (Guirado and 
Ruiz de Almodovar 2003, Raabe et al. 2012, Tucker et al. 1996). It has been suggested that 
individual radiosensitivity is under genetic control and the radiation-induced normal tissue 
reactions could be potentially predicted with the help of biomarkers (Andreassen et al. 2003, 
Andreassen et al. 2006, Ho et al. 2006, Schirmer et al. 2011).   
TGFβ1 is considered as key extracellular player for initiating and promoting adverse effects of 
radiotherapy (Martin et al. 2000). In plasma, elevated levels of TGFβ1 were suggested to be 
correlated with radiotherapy toxicity (Anscher et al. 2003, Zhao et al. 2008). However, findings 
were controversial (De Jaeger et al. 2004). Since tumors often produce high amounts of TGFβ1 
circulating levels of this cytokine may decrease with tumor shrinking during therapy (Zhao et 
al. 2008).  
Early response of cells toward radiation was assessed by in vivo experiments. Parenchymal and 
mesenchymal cells exhibited increased secretion of TGFβ1 when damaged by irradiation. 
Induction of TGFβ1 has been observed at the protein and messenger RNA(mRNA) level in pig 
skin 6 hours after γ-irradiation (16-64 Gy), and on mRNA level in mouse skin 6 hours after β-
radiation (50 Gy). Moreover, elevated TGFβ1 protein level was detected in irradiated rat small 
intestine and mouse mammary gland and sustained from 7 (for intestines) up to 26 ( for 
mammary gland) days (Martin et al. 2000).  
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Radiation-induced TGFβ1 expression can sustain after acute response and cause late radiation 
damage, particularly development of radiation fibrosis in irradiated skin (Bouquet et al. 2011). 
In general, via inhibition of epithelial cells and activation of fibroblasts TGFβ1 induces 
development of fibrous scars. TGFβ1-induced apoptosis results in parenchymal damage and 
fibrotic replacement of normal tissue, which affects various types of organs like intestine, 
bladder, lung, and liver (Martin et al. 2000). 
 
1.3 From transcription to activation and signaling of TGFβ1 
 
1.3.1 TGFβ1 expression  
Transcription of TGFβ1 is induced through the activation of cellular kinases JNK, p38 MAPK, 
Src, and ERK. Upon binding of transcription factors such as AP-1, Sp1, NF-kB, STAT-3, which 
are mediated by upstream cellular kinases and belong to a category of rapid acting transcription 
factors (Kim et al. 1990, Presser et al. 2013), transcription and translation starts with a TGFβ1 
precursor (SP-LAP- TGFβ1). The latter comprises a complex of 290 amino acids, which 
contains the TGFβ1 latency associated peptide (LAP) co-translated with the 112 amino acid 
sequence corresponding to the mature TGFβ1. A signal peptide of 29 amino acids precedes the 
LAP. This peptide chain is termed as pre-pro TGFβ1 (Janssens et al. 2005). 
 
1.3.2 Intracellular processing 
Processing of the TGFβ1 precursor (Fig. 1) starts with translocation to the rough endoplasmatic 
reticulum (ER) governed by the signal peptide, which is cut off there (Gentry et al. 1988, ten 
Dijke and Arthur 2007). This cutting occurs most likely between the positions Gly29 and 
Leu30. The released LAP-TGFβ1 monomers form disulfide-bonded homodimers within the 
ER. The protein structure is stabilized by several intramolecular disulfide bonds between 
cysteine residues. Further cysteine bonds link each the two domains of the mature TGFβ1 with 
one another and analogously the two LAP domains (Javelaud and Mauviel 2004, Marín-García 
2011, Munger et al. 1997, ten Dijke and Arthur 2007). These pro-TGFβ1 homodimers are then 
translocated to the Golgi apparatus and undergo glycosylation there. Moreover, in Golgi 
endoproteolytic cleavage between the LAP and the mature TGFβ1 is executed by furin type 
enzymes (Munger and Sheppard 2011). However, the two peptide fragments (homodimeric 
TGFβ1, 25 kDa, and homodimeric LAP, ~ 57 kDa) remain non-covalently associated termed 
"small latent complex" (SLC) of TGFβ1. A further protein transcribed from another genetic 
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locus, i.e. a latent TGFβ1 binding protein 1 (LTBP1, 190 kDa), can optionally join the SLC and 
the complex is then called "large latent complex" (LLC) of TGFβ1 (Kanzaki et al. 1998, Khalil 
1999, Maeda et al. 2002, Miyazono et al. 1991). In the LLC, LTBP binds to LAP via covalent 
disulfide bonds (Taipale et al. 1998). 
 
  
Fig. 1 Processing and cleavage of TGFβ1 precursor (modified according to Miyazono, 1991). 
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1.3.3 TGFβ1 secretion 
TGFβ1 can be secreted in two fashions, as SLC or LLC complex. Secretion as part of the SLC 
is less efficient (Dallas et al. 1994 Miyazono et al. 1991). In absence of LTBP, a major fraction 
of SLC is retained in the Golgi apparatus (Saharinen et al. 1999).  
TGFβ1 exports in conjunction with the LLC, which is the major route for most cells secreting 
TGFβ1 (Koli et al. 2001). Within 15 min after synthesis, LTBP binds via covalent disulfide 
bonds to the SLC resulting in LLC composing. Upon further 15 min, LLC is secreted whereby 
LTBP targets this complex by interactions with extracellular proteins to the ECM where it is 
stored (Miyazono et al. 1991). Particularly, the hinge region in the N-terminus of the LTBP 
facilitates targeting of the LLC to the extracellular location. An isopeptide bond, i.e. a covalent 
link between the side chains of acidic amino acids on the one and lysine on the other side, fixes 
the LTBP at ECM proteins (Annes et al. 2004, Unsold et al. 2001). Subsequently, proteolysis 
of LTBP in the protease-sensitive hinge region liberates SLC which can bind to the cell surface 
where active TGFβ1 is released (Taipale et al. 1998).  
 
1.3.4 TGFβ1 activation  
Upon binding of the SLC to the cell surface, mature TGFβ1 dissociates from LAP in order to 
become biologically active, i.e. to bind to the cellular receptors and to elicit multifunctional 
activities by launching signal cascades (Annes et al. 2003, Kubiczkova et al. 2012).  
Several mechanisms for the activation of TGFβ1 are known, e.g. cleavage by furin (Dubois et 
al. 1995) and other proteases such as plasmin, thrombin, plasma transglutaminases or 
endoglycosylases (Jenkins 2008). Cleavage mostly occurs at the carboxyl-terminal site of LAP 
in the LAP-TGFβ1 amino acid sequence. E.g. furin, an ubiquitously expressed convertase, 
mostly localized in the trans-Golgi apparatus, processes the pro-protein at the carboxyl site of 
the consensus R-H-R-R cleavage motif (Dubois et al. 1995). 
Alternatively, mature TGFβ1 can be released by physico-chemical interactions of the LAP with 
thrombospondin-1 (Murphy-Ullrich and Poczatek 2000), integrins (ITGs) (Mu et al. 2002, 
Munger et al. 1999, Sheppard 2005), hormones, vitamin A derivates, extreme pH (2-8), heat, 
chaotropic substances like SDS and urea (Khalil 1999). Moreover, ionizing radiation and 
reactive oxygen species (ROS) can be involved in TGFβ1 activation (Barcellos-Hoff and Dix 
1996). Via oxidation of specific amino acid residues in the LAP ROS confer conformational 
changes resulting in release of active TGFβ1. This action of ROS seems to be specific for the 
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TGFβ1 isoform (Jobling et al. 2006). Upon activation, TGFβ1 exerts functions via further 
signaling (Kubiczkova et al. 2012). 
 
1.3.5 Signal cascade triggered by active TGFβ1 
The mechanisms elicited by receptor binding of active TGFβ1 are schematically illustrated in 
the Fig. 2. Active TGFβ1 binds to the TGF beta type II receptor (TGFβR-II), which recruits a 
type I receptor (TGFβR-I). TGFβR-I and TGFβR-II are transmembrane serine/threonine 
kinases and form a dimeric complex on the cell surface. They have a cysteine rich extracellular 
domain, a transmembrane domain and an intracellular serine/threonine kinase domain. The 
TGFβR-II is a constitutively active kinase and activates and phosphorylates TGFβR-I kinase in 
a region rich in glycine and serine/threonine residues termed the GS domain (Dennler et al. 
2002, Massague and Gomis 2006). In turn, the type I receptor activates the regulatory Smad 2 
and 3 transcription factors (R-Smads) by phosphorylation. Phosphorylated Smads 2/3 bind to 
Smad 4 and shuttle to the cell nucleus. In the nucleus, they form a nuclear complex with other 
co-transcription factors causing stimulation or inhibition of target genes depending on the type 
of co-factors present (Karathanasi et al. 2013, Massague 1998, Massague and Gomis 2006, 
Massague and Wotton 2000). 
Fig. 2 TGFβ1–Smad signaling from the cell membrane to nucleus (modified according to Massague 1998). 
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1.4 Inherited genetic variability in TGFB1 and radiotoxicity 
It was suggested that TGFβ1 expression is under the genetic control and several single 
nucleotide polymorphisms (SNPs) in TGFB1 gene were associated with the impact of 
circulating TGFβ1 (Grainger et al. 1999) and radiotoxicity (Ho et al. 2006, Schirmer et al. 2011, 
Schirmer et al. 2012).  
Most studies have evaluated the risk of late side effects of radiotherapy in association with two 
TGFB1 SNPs in high linkage disequilibrium (LD) in Caucasians: -509C>T (rs18000469) and 
Leu10Pro (rs1800470). However, the findings are controversial and more studies are required 
(Barnett et al. 2012, Raabe et al. 2012, Rosenstein 2011, Schirmer et al. 2011, Schirmer et al. 
2012, Zhu et al. 2013). 
Less is known about associations of TGFβ1 SNPs with acute organ toxicity. Zhang and 
colleagues showed the significant association between TGFβ1-509C/T polymorphism and a 
higher radiation-induced esophageal toxicity risk in patients with locally advanced lung cancer 
treated with radiotherapy (Zhang et al. 2010). Moreover, relationship of the TGFβ1 Arg25Pro 
polymorphism and high-grade acute organ toxicity in patients with rectal cancer receiving 
neoadjuvant radiochemotherapy (N-RCT) was reported. In two independent cohorts, all 
patients carrying the TGFβ1 Pro25 allele experienced acute toxicity in organ systems typically 
affected by local radiation therapy. Moreover, the effect of the variant was observed regardless 
of concomitant chemotherapy. Therefore, Arg25Pro polymorphism was suggested as a 
promising biomarker for individual treatment stratification in N-RCT (Schirmer et al. 2012). 
 
1.4.1 Arg25Pro polymorphism 
The human gene encoding TGFβ1 protein is located on the long (q) arm of human chromosome 
19 at cytoband 13.1 and has seven exons (Fig. 3) (Derynck et al. 2001). The entire TGFB1 gene 
transcript coding for a signal peptide, LAP, and mature TGFβ1 features 23,166 base pairs (bp).  
Arg25Pro polymorphism (rs1800471, position +74, codon 25) is located in exon 1 of the TGFβ1 
ligand in the signal peptide, which is cleaved during maturation of TGFβ1 at codon 29. This 
polymorphism corresponds to a non-synonymous substitution of the big polar amino acid 
arginine for the small apolar proline (Stoll et al. 2004). This exchange could affect the adjacent 
cleavage site (Awad et al. 1998).  
1 Introduction  11 
 
 
Fig. 3 Schematic structure of the TGFB1 genetic locus on human chromosome 19.          
The human TGFB1 gene is located in chromosome 19 at position 13.1 and encodes 7 exons. The TGFB1 gene is 
translated into an inactive TGFβ1 precursor containing 390 amino acids (AA) with a signal peptide (AA 1-29), a 
LAP (AA 30-278) and a mature TGFβ1 (AA 279-390). The Arg25Pro polymorphism is located in the signal 
peptide. The sense strand of the transcribed product corresponds to the reverse strand with respect to the 
chromosomal orientation.  
 
Few studies have examined Arg25Pro polymorphism effects. This SNP was reported to be 
associated with chronic inflammation, fibrosis (Awad et al. 1998, Cambien et al. 1996, Khalil 
et al. 2005, van de Wetering et al. 2006) and radiotoxicity (Peters et al. 2008, Schirmer et al. 
2012). However, not all studies are consistent (Berndt et al. 2007, Densem et al. 2004, Ogawa 
et al. 2007).  
Awad and colleagues observed an association between the Arg25Pro polymorphism and TGFβ1 
production in vitro. Stimulated TGFβ1 production from peripheral blood leucocytes was higher 
for Arg25. Moreover, presence of the Arg25 variant predisposed to the development of pre-
transplant lung fibrosis as also to the fibrosis after lung transplantation (Awad et al. 1998). 
Similarly, progressing renal failure with proteinuria, elevated circulating TGFβ1 levels and 
glomerulosclerosis was more frequent in homozygotes for Arg25 (Khalil et al. 2005).  
Other studies claimed unfavorable effects of the Pro25 variant, which affects about 10% of the 
Caucasian population. Van de Wetering and collegues observed an increased risk of developing 
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end-stage renal failure for Pro25 carriers (van de Wetering et al. 2006). Additionally, the Pro25 
allele was associated with increased risk of myocardial infarction (Cambien et al. 1996). 
Moreover, patients with prostate cancer carrying the Pro25 variant developed side effects after 
radiation like erectile dysfunction and late rectal bleeding more frequently (Peters et al. 2008). 
Furthermore, Schirmer and colleagues observed an increased risk of acute radiotherapy-related 
toxicity in patients with rectal cancer carrying the Pro25 allele (Schirmer et al. 2012). 
If independently confirmed, identification of patients harboring the Arg25Pro polymorphism 
may help to predict risks for TGFβ1-related side effects of therapies. In addition, to understand 
modes of actions and for possible pharmacological interventions detailed studies are required 
to determine possible molecular mechanisms how the Arg25Pro polymorphism may exert its 
effects. 
 
1.5 Aim of this work 
The aim of my thesis work was to clarify possible molecular mechanisms behind the clinical 
association of the Arg25Pro polymorphism in the TGFB1 gene. The hypothesis was that the 
amino acid exchange Arg25Pro located in the signal peptide might affect TGFβ1 translation, 
secretion, or post-translational processes such as cellular trafficking or whether it modulates 
TGFβ1 activation from its latent complex.  
Therefore, to investigate allele-specific effects of the Arg25Pro polymorphism overexpression 
of Arg25 and Pro25 in a model cell line had to be set up. The generated cell models should be 
characterized to evaluate the correct genome integration and an equal mRNA expression rate 
for both variants. Using these constructs, allele-specific functional effects had to be evaluated. 
It should be investigated whether translation, secretion, trafficking or activation of TGFβ1 is 
different for the Pro25 in comparison to the Arg25 allele. These issues should be addressed both 
with and without simulation of radiotherapy as used in daily treatment of the patients. 
 
 





Accu-jet® Brand, Wertheim 
Bacteria Incubator-Incudrive  Schütt, Göttingen 
Biofuge fresco  Heraeus, Hanau  
Biofuge pico  Heraeus, Hanau  
BioPhotometer 6313 Eppendorf, Hamburg  
Cell counting chamber (Neubauer improved) Schütt, Göttingen 
Centrifuge 5810R  Eppendorf, Hamburg 
Centrifuge JA-20 Rotor  Beckman, München  
CO2-Incubator BBD 6220  Heraeus, Hanau 
Concentrator 5301  Eppendorf, Hamburg  
Electroblotting apparatus Fastblot B43 Biometra, Göttingen 
Electrophoresis chamber (Mighty Small II) Hoeffer, Holliston, USA 
Electroporator Gene Pulser II  BioRad, Hercules, USA  
Fine weight machine  Sartorius, Göttingen  
Fluor-S™ MultiImager  BioRad, Hercules, USA  
Freezer V.I.P.® Series -86°C Ultra Low  Sanyo Electric Co Ltd., Japan 
Gel chamber (ComPhor Mini) Biozym, Oldendorf 
Gel chamber (Mighty Small SE Dual Gel Caster)   Hoeffer, Holliston, USA 
Gel electrophoresis power supply  
(Standard Power Pack P 25) 
Biometra, Göttingen 
Labofuge 400R  Heraeus, Hanau  
Magnetic stirrer (IKAMAG RET) IKA, Staufen  
Membrane vacuum pump Vacuubrand, Wertheim  
Microplate Reader (96-well plate, Tecan ULTRA) Tecan, Crailsheim 
Microscope Axiovert 40 CFL  Zeiss, Jena 
Microscope Olympus IX81 
Olympus Europa Holding 
GmbH, Hamburg 
Microscope Telava l31 Zeiss, Jena 
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Microwave MWS 2820 Bauknecht, Schorndorf 
Minishaker MS 2 IKA, Staufen 
Multipipette plus  Eppendorf, Hamburg 
Nanodrop cuvette  Implen, München 
PCR-Gradient-Cycler (384-well plate), Master-Cycler Eppendorf, Hamburg 
PCR-Gradient-Cycler (96-well plate), PTC-200 Peltier 
Thermal Gradient Cycler 
MJ Research/BioRad, 
Hercules, USA 
Pipettes (0.1 - 2.5 µl; 0.5 - 10 µl; 10 - 100 µl; 
100 - 1000 µl; 1000 - 2500 µl)  
Eppendorf, Hamburg 
pH meter CG 822 Schott Geräte, Mainz 
PTC-200 Peltier  
MJ Research/BioRad, 
Hercules, USA  
QiaCube  Qiagen, Hilden 
Sequencer ABI PRISM® 3100 Genetic Analyser 
Applied Biosystems, 
Darmstadt 
Shaker for bacteria K2 260 basic  IKA, Staufen 
Stereomicroscope Stemi 1000  Zeiss, Jena 
Sterile Bench-Clean Air type DFL/REC4 KL2A  Mahl, Trendelburg  
TaqMan 7900HT  
Applied Biosystems, 
Darmstadt 
Thermomixer 5436  Eppendorf, Hamburg 
Transilluminator TI 2  Biometra, Göttingen 




Vertical-Autoclave KSG 40/60  KSG, Olching  
Vertical-Autoclave: FV  Tecnorama, Fernwald 
Water bath GFL 1083  Schütt, Göttingen  
Xstrahl RS225 GulmayMedical Limited, UK  
* Country was not mentioned for Germany. 
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2.2 Used laboratory materials 
Laboratory materials Delivery/manufacturer* 
Absolute QPCR Seal (Optical folie for Taqman)  Thermo Scientific, UK  
Adhesive PCR Foil Seals  ABgene, Epsom 
CryoTubes (2 mL) Nunc, Thermo Scientific, Denmark 
Culture flask 25 cm² , 75 cm²  Sarstedt, Nümbrecht 
Dialyse membrane filter VSWP01300  Millipore, Bedford, USA  
Electroporation cuvette 2 mm  PeqLab, Erlangen  
Filter paper #2668  Schleicher und Schuell  
Filter paper #2CHR  Schleicher und Schuell  
Flat cap strips, 12er  ABgene, Epsom  
Flat cap strips, 8er  ABgene, Epsom  
Freezing container, Nalgene®, Mr. Frosty  Sigma-Aldrich, Deisenhofen  
Glass pasteur pipette 230 mm  WU, Mainz  
Lid for ELISA plate Nunc, Roskilde, Dänemark 
Filter Minisart 2000, 0.2 μm  Sartorius, Göttingen  
Filter Minisart–plus, 0.2 μm  Sartorius, Göttingen  
Filter pipett tip, sterile  Kisker, Steinfurt  
Cell strainer, 40 micron BD Falcon (352340) 
Multidishes 6 und 12-well  Nunc, Wiesbaden  
Nitrocellulose filter (13 mm, 0.025 m) Millipore, Schwalbach 
Parafilm®  Brand, Wertheim  
Petri dish  Sarstedt, Hamburg  
Pipette tips (10 μl, 100 μl, 1000 μl, 2500 µl)  Sarstedt, Hamburg  
Pipette tips for multipipette (0.1; 0.2; 0.5; 1.0; 2.5; 
5 ml) 
Eppendorf, Hamburg 
Plate loader for sephadex  Millipore, Schwalbach  
Plate retainer for sequencing  Applied Biosystems, Darmstadt  
Plate 96 Well, Thermo-Fast ABgene, Epsom  
Plate 96 Well, Millipore MAHV N45 Millipore, Bedford, USA 
Plate 96 Well for ELISA, Nunc Maxisorp Nunc, Roskilde, Dänemark 
Plate 96 Well, Millipore MANU 030 PCR- Millipore, Bedford, USA 
Plate 384 Well, FrameStar®  4titude, Wotton  
Plate 384 Well, Thermo fast  ABgene, Epsom  
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PVDF membranes/Westran® S (0.45 µm) Schleicher & Schuell, Dassel 
Sterile pipette (5 ml, 10 ml, 25 ml)  Sarstedt, Hamburg  
Sterile polypropylen-tube 15 ml  Greiner, Frickenhausen  
Sterile polypropylen-tube 50 ml  Sarstedt, Hamburg  
Whatman papers (Filter paper Nr. 2668)  Schleicher und Schüll, Dassel 
* Country was not mentioned for Germany.  
 
2.3 Reagents, kits, media 
Reagents, kits, media Delivery/manufacturer  
1 kb Size standard ladder (for agarose gel)  Rapidozym, Berlin  
100 bp Size standard ladder (for agarose gel) Rapidozym, Berlin  
2-Mercaptoethanol ≥ 99%  Sigma-Aldrich, Deisenhofen  
40% (w/v) Acrylamide:Bisacrylamide/  
Mix 37.5:1  
Biomol, Hamburg  
5- Fluorouracil (50 mg/ml) Medac GmbH, Hamburg 
5 x HOT FIREPol® EvaGreen®  
qPCR Mix Plus (ROX)   
Solis BioDyne, Tartu, Estonia 
Agar (for bacteriology)  AppliChem, Darmstadt  
Agarose Ultra Pure (for gel electrophoresis) Invitrogen, Karlsruhe  
Ampicillin 99%  AppliChem, Darmstadt  
Bicinchoninic acid solution Sigma-Aldrich, Deisenhofen  
BigDye® Sequencing Kit  
(fluorescence based Sanger sequencing)   
Applied Biosystems, Darmstadt 
Bovine serum albumin (BSA)  Sigma-Aldrich, Deisenhofen  
Bromphenolblue Na-Salt  Roth, Karlsruhe  
Chloroform ≥ 99.8%  J.T. Baker, Phillipsburg, USA  
Complete, EDTA-free  
(protease inhibitor cocktail tablets) 
Roche, Mannheim 
Coomassie Brilliant Blue R 250  BioRad, München  
DNeasy Blood & Tissue Kit (for DNA extraction)  Qiagen, Hilden 
DAPI Invitrogen, Karlsruhe 
Dimethyl sulfoxide (DMSO)  AppliChem, Darmstadt  
DMEM   Invitrogen, Karlsruhe 
dNTP Set  ABgene, Hamburg  
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EDTA 0.5 M in water solution  Sigma-Aldrich, Deisenhofen  
EDTA pure  Merck, Darmstadt  
Ethanol 96%  Merck, Darmstadt  
Ethanol denatured 99% (disinfection agent)  Chemie-Vertrieb, Hannover  
Ethidium bromide 1% in H2O (for electrophorese)  Merck, Darmstadt  
Exonuclease I E.coli (ExoI) (20 U/μl)  Fermentas, St. Leon-Roth  
Expand Long Template PCR System   Roche, Mannheim 
Fetal bovine serum (FBS)  Gibco/Invitrogen, Karlsruhe 
FuGene 6® (transfection agent)  Roche, Mannheim  
GeneScan LIZ 120  
(size standard ladder for SNaPshotTM) 
Applied Biosystems, Darmstadt  
Glycerol 85 %  Central Pharmacy, University 
medical center Göttingen  
Helipur® H plus N (desinfection agent) Braun, Melsungen  
Human LAP (TGFβ1) Ready-Set-Go  eBioscience, San Diego, USA 
Human/Mouse TGFβ1 ELISA Ready-Set-Go®  eBioscience, San Diego, USA 
Hygromycin B (50 mg/mL)  Invitrogen, Karlsruhe  
Isoamylalcohol 98%  Schuchardt, Hohenbrunn  
Isopropanol ≥ 99.9%  Merck, Darmstadt  
Kanamycin ≥ 750 U/mg   AppliChem, Darmstadt  
KOD HotStart DNA Polymerase  Novagen Merck, Darmstadt 
Ligate-ITTM Rapid Ligation Kit  Usb, Staufen 
Neodisher® A 8, cleaning powder  Chem. Fabrik Dr. Weigert, Hamburg 
PBS  Invitrogen, Karlsruhe 
PBS Powder (Dulbeccos 10x)  AppliChem, Darmstadt  
Penicillin/Streptomycin-Solution  Invitrogen, Karlsruhe  
PhosStop (phosphatase inhibitor cocktail tablets) Roche, Mannheim 
Polylysin-D-hydrobromide (for cell culture) Sigma-Aldrich, Deisenhofen  
Ponceau S 10x (for blotting membrane staining) Carl Roth, Karlsruhe 
Q-Solution Qiagen, Hilden 
QIAquick Gel Extraction Kit  Qiagen, Hilden 
QIAquick PCR Purification Kit  Qiagen, Hilden 
Random hexanucleotide primers dN6  Roche, Mannheim  
Rnase-Zap Sigma, St.Louis, USA 
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RNeasy Plus Mini Kit  Qiagen, Hilden 
RLT-Plus buffer Qiagen, Hilden 
Roti®-Histofix 4%  Carl Roth, Karlsruhe  
Roti®-Block -  Carl Roth, Karlsruhe 
SeeBlue® Plus2 Prestained Standard Invitrogen, Karlsruhe 
Sephadex™ G-50 Superfine  Amersham Bioscience, Freiburg  
Shrimp Alkaline Phosphatase (SAP) (1 U/μl)  USB, Staufen  
SnapShotTM Multiplex Kit  Applied Biosystems, Darmstadt 
Sodium chloride  Merck, Darmstadt  
S.O.C. media (for bacterial transformation) Invitrogen, Karlsruhe 
Sulfuric acid Merck, Darmstadt  
Super Script II Reverse Transcriptase  Invitrogen, Karlsruhe 
Supersignal® West Pico Kit   Thermo Scientific, Schwerte 
T4 DNA Ligase  MBI Fermentas, St. Leon-Roth  
TEMED ≥ 99%  Sigma-Aldrich, Deisenhofen  
TopTaq DNA Polymerase  Qiagen, Hilden 
Tris 100% Roth, Karlsruhe 
Triton X-100  Roth, Karlsruhe  
Trypan blue -solution (0.4 %)  Sigma-Aldrich, Deisenhofen  
TrypLE™ Express  Gibco/Invitrogen, Karlsruhe  
Tween 20 (Polyoxyethylen-Sorbit-Monolaurat)  BioRad, München  
Wheat Germ Agglutinin, Alexa Fluor® 488 
Conjugate 
Invitrogen, Carlsbad, USA 
Wheat Germ Agglutinin, Alexa Fluor® 594 
Conjugate 
Invitrogen, Carlsbad, USA 
Yeast extract AppliChem, Darmstadt 
Zeocin  Invitrogen, Karlsruhe  
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2.4 Antibodies  
Antibody  Dilution  Application Manufacturer  
 Primary antibodies 
TGFβ1 1:1000  Western blotting, 
Immunocytochemistry 
Cell Signaling, 
Danvers, USA  
FLAG M2  1:1000 Western blotting,  
Immunocytochemistry 
Cell Signaling, 
Danvers, USA  
GAPDH  1:10000  Western blotting   Serotec  
 Secondary antibodies 
Anti-mouse IgG 
HRP-conjugated  
1:10000 Western blotting Cell Signaling, 
Danvers, USA  
Anti-rabbit IgG-
HRP-conjugated  
1:10000 Western blotting Cell Signaling, 
Danvers, USA 
Anti-mouse IgG 
Alexa Fluor® 488  
1:400  Immunocytochemistry Life Technologies, 
Carlsbad, USA 
Anti-mouse     
Cy3-conjugated 
antibody 
1:400 Immunocytochemistry Jackson Immuno 
Research, West Grove, 
USA 
* Country was not mentioned for Germany. 
 
2.5 Restriction enzymes 
Restriction enzyme  Delivery/manufacturer* 
BamHI Fermentas, St. Leon-Roth 
BstXI New England Biolabs, Beverly, USA 
DpnI  New England Biolabs, Beverly, USA  
HincII New England Biolabs, Beverly, USA 
HindIII  Fermentas, St. Leon-Roth  
NotI  New England Biolabs, Beverly, USA  
SacI  Fermentas, St. Leon-Roth  
SalI Fermentas, St. Leon-Roth 
XhoI  Fermentas, St. Leon-Roth  
XmaI  New England Biolabs, Beverly, USA  
* Country was not mentioned for Germany. 
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2.6 Strains of bacteria 
Strain of bacteria  Origin Application  Delivery/ 
manufacturer* 
Top10  
(One shot TOP10  
Electro-comp. E.coli)  
Escherichia 
coli 




Electrocompetent Invitrogen,  
Karlsruhe 
* Country was not mentioned for Germany. 
 
2.7 Vectors  
Vector  Resistance Delivery/manufacturer* 
pOTB7/TGFB1 Chloramphenicol 
SourceBioscience,  
Nottingham, UK  
pcDNA5/FRT  Ampicillin Invitrogen, Karlsruhe  
pEX-A/FLAG Ampicillin Eurofins MWG Operon, Ebersberg 
pOG44 Ampicillin Invitrogen, Karlsruhe 
* Country was not mentioned for Germany. 
 
2.8 Cell lines  
Cell line Origin Manufacturer* 
Flp-InTM T-REx HEK 293  
(Embryonic kidney cell line, which 
contains Flp Recombination 




Primary skin fibroblasts Human 
Departments of Dermatology and 
General Surgery of University 
Medical Center Göttingen 
NIH 3T3  
(Embryonic fibroblast cell line) 
Mouse 
Institute for Pharmacology, 
University Medical Center Göttingen 
* Country was not mentioned for Germany. 
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2.9 Buffers and solutions 
TBE buffer (pH 8.3)   
 Tris  100 mM 
 Boric Acid  100 mM 
 EDTA  3.0 mM 
 
Loading dye (5 x) for agarose gel electrophoresis  
 Glycerol 30% (v/v) 
 EDTA 50  
 Bromphenol blue 0.25% (v/v) 
 Xylene cyanol 0.25% (v/v) 
 
Resuspension buffer (B1) for plasmid mini-preparation  
 Tris-HCl (pH 8.0)  l50 mM 
 EDTA  10 mM 
 RNase A  100 μg/ml  
(store at 4°C)  
 
Lysis buffer (B2) for plasmid mini-preparation   
 NaOH  200 mM 
 SDS  1% (w/v)  
 
Neutralization buffer (B3) for plasmid mini-preparation  
 Potassium acetate (pH 5.5) 3 M  
 
BSA stock solution (1mg/ml)   
 BSA  50 mg  
 1x RIPA buffer  50 ml  
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RIPA buffer   
 Tris-HCl  50 mM  
 NaCl  150 mM  
 EDTA  1 mM  
 NP-40  1%  (v/v)  
 Na-deoxycholate  0.25%  (w/v)  
 PMSF (optional)  1 mM  
 
Cupric sulfate pentahydrate solution (CuSO4 x 5 H2O)   
 Cupric sulfate 4%  2 mg  
 ddH2O  50 mL  
 
SDS-PAGE loading buffer (4x)   
 Tris-HCl (pH 6.8) 581 mg  
 Bromphenolblau  1.6 mg 
 DTT 400 mM 1.234 g  
 Glycerol 28 % (v/v) 6.59 ml of 85% 
Glycerol 
 SDS  1.6 mg  
 ddH2O Add to 20 mL 
 
Run buffer (pH 8,4) for Western blotting   
 Tris-HCl 3.03 g 
 Glycin 14.41 g 
 SDS 1 g 
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Transfer buffer (pH 9) for Western blotting   
 Tris-HCl  48 mM  
 Glycin  39 mM  
 SDS  0.0374% (w/v)  
 Methanol  15%  
 ddH2O  Add to 1 L  
 
Blocking solution for Western blotting   
 Roti®-Block 5 mL 
 ddH20 45 mL 
 
TBS buffer 10x (pH =7,6) for Western blotting   
 Tris-HCl (200 mM) 24.2 g 
 NaCl (1,505 M) 88 g 
 ddH2O Add to 1 L 
 
TBST buffer (1x) for Western blotting   
 TBS (10x) 100 ml 
 Tween 20 500 µl 
 ddH2O Add to 1 L  
 
Luria-Bertani (LB) media for bacterilogy   
 Trypton  10 g 
 Yeast extract  5 g 
 NaCl  5 g 
 ddH2O  Add to 1 L 
(store at 4°C) 
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2.10  Primers 
 
Tab. 1 Point-mutation primers  
Primer name Sequence 
TGFB1-Pro25-for 5ꞌ-GTGCTGACGCCTGGCCCGCCGGCCGCGGGACTA-3ꞌ 
TGFB1-Pro25-rev 5ꞌ-TAGTCCCGCGGCCGGCGGGCCAGGCGTCAGCAC-3ꞌ 
The mutated base is bolded and genetic codons are underlined 
 
Tab. 2 Primers for amplification and subsequent insertion of TGFB1 into pcDNA5.1 vector 
Primer name Sequence 
TGFB1-f_Hind-III 5ꞌ-GGGGGGCGAAGCTTCCCCCATGCCGCCCTCCGG-3ꞌ 
TGFB1-r_Xho-I 5ꞌ-GGTGGGCTCGAGGCACGGGTGTCCTTAAATAC-3ꞌ 
Restriction sites are marked in italic 
 
Tab. 3 Primers for cloning of MetFLAG in signal peptide of TGFβ1  








Sequence of the FLAG epitope is bolded and underlined 
 







Sequence of the FLAG epitope is bolded and underlined.     
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Tab. 5 Primers for validation of chromosomal integration of the TGFB1 constructs in the genome of the 
HEK 293 T-Rex cells 






Tab. 6 Sequencing primers 






Tab. 7 Primers for SNaPShotTM reaction 
Primer name Sequence 
                                     Primers for fragment amplification 
pcDNA5-TGFB1-for 5ꞌ-AGCTGGCTAGCGTTTAAACTTAAGC-3ꞌ 
TGFB1-human-rev 5ꞌ-TGTTGCTGTATTTCTGGTACAGCTC-3ꞌ 
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Tab. 8 Primers for qRT-PCR 
Primer name Sequence 
TGFB1-human-for  5ꞌ-GGTACCTGAACCCGTGTTGCT-3ꞌ 
TGFB1-human-rev 5ꞌ-TGTTGCTGTATTTCTGGTACAGCTC-3ꞌ 
GAPDH-human-for  5ꞌ-CCCTTCATTGACCTCAACTACAT-3ꞌ 





3100 Data Collection Software  Applied Biosystems, Darmstadt  
Adobe Photoshop  Adobe Systems GmbH, München  
Clone Manager Suite  SECentral, Cary NC, USA 
CorelDRAW X3  Corel Corporation, Ontario, Canada 
DNA Sequencing Analysis  Applied Biosystems, Darmstadt 
EndNote X7  Thomson Reuters, Philadelphia PA, USA 
GeneMapper, v 3.7 Applied Biosystems, Darmstadt 
Oligo, v. 6.58 Molecular Biology Insights, Cascade CO, 
USA 
Olympus xcellence pro Olympus soft imaging solutions GmbH, 
Münster  
Quantity One S, v. 4.3.1  BioRad, München 
SDS 2.1 Applied Biosystems, Darmstadt 
SPSS, v. 12.0 SPSS Inc., Chicago, USA  
Staden Package Medical research council laboratory of 
molecular Biology, Cambridge, UK 
XFluor4  Tecan, Crailsheim 
SignalP 4.1 prediction tool http://www.cbs.dtu.dk/services/SignalP/ 
*Country was not mentioned for Germany. 
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3 Methods 
 
3.1 DNA techniques 
 
3.1.1 Polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR) is a molecular technique for enzymatic replicating of DNA 
in vitro. The typical reaction components are DNA template, DNA polymerase, oligonucleotide 
primers, nucleotides, and reaction buffer. To improve the amplification of templates with high 
GC content Q-Solution can be used. Standard PCR involves three steps: The first step is 
denaturation of the DNA template into single stranded molecules (performed at 95°C). The 
second step is annealing of the primers with the denatured target DNA. Depending on the size 
and composition of the primers, the second step is usually performed at temperatures between 
50-70°C. The third step is extension of a new DNA strand complementary to the DNA template 
strand using DNA polymerase by adding dNTPs in 5'- to 3'-direction at 65-75°C. The 
temperature depends on the DNA polymerase used and the time depends on the length of the 
expected product.  
Under optimal conditions, the amount of DNA target is doubled per cycle leading to exponential 
amplification of the specific DNA fragment. In this work, 18 to 35 cycles depending on the aim 
of the PCR were carried out. As PCR enzymes KOD Hot Start DNA polymerase, Top Taq 
polymerase, and ExpandLong polymerase were used. To determine the PCR conditions 
(optimal annealing temperature, with or without Q-solution) gradient PCR was performed. The 
PCR reactions were carried out in gradient thermal cyclers. The optimal PCR conditions 
(annealing temperature, optional use of Q solution) were defined by visualization on agarose gels. 
 
3.1.2  Agarose gel electrophoresis 
Agarose gel electrophoresis is an effective way of separating the different sized fragments of 
DNA for analytical or preparative purposes, such as cloning, DNA sequencing. In gel 
electrophoresis nucleic acid molecules are separated by the electric field, where the negatively 
charged molecules migrate toward anode (positive) pole. The migration flow is determined by 
the molecular weight, where the small weight molecules migrate faster than larger ones. To 
prepare the gel, appropriate amount of agarose (0.8%-2,5%) was dissolved in boiling TBE 
buffer. The solution was cooled to approximately 55°C. Then, 0.5 μg/mL ethidium bromide 
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(EtBr) was added and mixed using magnet stirrer. EtBr is a fluorescent dye and it intercalates 
between nucleic acids bases and allows to detect nucleic acid fragments in gels. Afterwards, 
the agarose solution was poured into the casting tray. Gel combs were placed in the gel tray to 
form the wells for samples. After the gel solidified (about 15-30 min), DNA samples were 
mixed with 1 x loading dye and pipetted into the wells of the gel. DNA size marker (100 bp – 
1 kb DNA Ladder) was used to estimate the size of the analyzed DNA fragments. The 
electrophoresis was performed with 120 V for 30-40 min (depending on the size of DNA 
fragments) using a ComPhor L Mini Gel chamber. The obtained DNA bands were visualized 
by Fluor-S™ MultiImager using Quantity One® S Version 4.3.1 software. 
 
3.1.3 DNA purification from agarose gel 
After separating DNA fragments by length in the agarose gel electrophoresis, DNA was 
visualized under UV-light using transilluminator TI2. The gel slice containing the desired DNA 
band was excised and transferred to a pre-weighed 1.5 mL Eppendorf tube. The slices should 
not exceed 200 mg of 2% agarose gel. The obtained gel fragments were purified using 
QIAquick Gel Extraction Kit with QiaCube robot according to the manufacturer’s instructions. 
 
3.1.4 Total genomic DNA isolation 
Total genomic DNA extraction from the cells was performed using DNeasy Blood & Tissue 
Kit with the QiaCube robot according to the manufacturer's instructions. In order to obtain 
optimal DNA quality, about 1 x 106 cells resuspended in 100 µl of PBS buffer were used. The 
amount of extracted DNA was determined by photometric quantification (see section 3.1.5) 
 
3.1.5 DNA quantification 
DNA concentration was determined photometrically by measuring absorbance at 260 nm with 
the BioPhotometer using an Implen-Nanodrop cuvette. Therefore, 3 µl of the sample were 
pipetted in the cuvette. Additionally to the extinction of 260 nm, the absorbance ratio of 
260/280 nm, which expresses the purity of DNA, was measured. The DNA samples with 
260/280 nm ratio above 1.6 were considered as pure and could be used for further experiments. 
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3.1.6 Site-directed mutagenesis 
Site directed mutagenesis is a method for introducing mutations (either single base pairs or 
larger insertions, deletions, or substitutions) into a DNA sequence to localize the effects of 
mutations on genes. Our point mutation was a single amino acids exchange from Arg to Pro at 
position 25 in the signal peptide of the TGFB1 gene (rs1800471). In order to conduct the side 
directed mutagenesis, the vector with inserted cDNA of TGFB1 gene with wild type allele 
(pOTB7/TGFB1; Clone 3356605/IRAU12D01; SourceBioscience, Nottingham, UK) was 
purchased. To introduce mutation, pOTB7/TGFB1 plasmid was amplified by PCR using the 
KOD Hot Start DNA Polymerase Kit and point-mutation primers (see section 2.10, Tab. 1). 
PCR reaction mixture and PCR conditions are shown in Tab. 9 and Tab. 10. 
Digestive enzyme DpnI was used to digest the parental DNA template, which is methylated. 
DpnI enzyme recognizes methylated residue in its target sequence (5´-Gm6ATC-3´) and 
cleaves bacterially generated parental plasmid but not the PCR product. For this reason, PCR 
product was incubated with 1,5 μl of DpnI for 1 h at 37°C and again 1 μl of this enzyme was 
added for next 1 h. Afterwards, the PCR product was dialyzed for 30 min and then transformed 
in E. coli TOP 10 strain by electroporation. The pOTB7/TGFB1 plasmids carrying the required 
mutation and wild type were isolated by mini-preparation. To check the correctness and exclude 
other mutations in the plasmid, the entire TGFB1 open reading frame (ORF) for both constructs 
wild type and variant was sequenced. The sequencing primers are listed in section 2.10, Tab. 6. 
Tab. 9 PCR-reaction mixture used for site-directed mutagenesis 
Reagent Volume (µl) 
10 x buffer  5 
dNTPs (2 mM)  5  
MgSO4 (25 mM)  2  
Q-Solution (optional) 10  
Forward-Primer (10 nM)  1.3  
Reverse-Primer (10 nM)  1.3 
Plasmid DNA (50 ng/μl)  1  
KOD HotStart Polymerase (1.0 U/μl)  1  
ddH20  Add to 50  
Final volume  50  
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Tab. 10 PCR conditions used for site-directed mutagenesis 
Phase  Duration  Temperature  
Initial Denaturation  3 min  95°C  
Denaturation   30 sec  95°C  
Annealing  30 sec  60°C  
Elongation  1 min 30 sec  72°C  
Cool down  for ever  8°C  
 
3.1.7 Restriction digestion  
Restriction digestion was performed to cleave DNA at specific sequences (restriction sites) 
using restriction enzymes for analytical and preparative purposes. The correctness of the 
cleaved DNA fragments was verified by agarose gel electrophoresis. 
3.1.7.1  Analytical digestion 
Analytic digestion was performed with at least three different digestion enzymes that excise 
plasmid within several restriction sites. The number and sizes of the yielded fragments after 
digestion were defined by the number of recognition sites.  
Reaction mixture (Tab. 11) was incubated for 1 h at recommended temperature for the optimal 
enzyme activity. Subsequently, the reaction mixture was run on the agarose gel electrophoresis. 
 
Tab. 11 Reaction mixture for analytic digestion 
Reagent  Volume (µl)  
10 x Restriction buffer  1  
BSA (optional)  0.1  
DNA (~1 μg) 1 
Enzyme  1   
ddH2O  Add to 10   
Final volume  10   
 
19 x 
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3.1.7.2 Preparative digestion 
The aim of the preparative digestion was to generate the "blunt ends" as well as the matching 
overhangs, called "sticky ends" in the insert fragment and vector. This was achieved by 
appropriate enzyme cleavage and allowed insertion of the fragment into the vector in the further 
ligation step. 
Briefly, dependent on the activity of the applied digestion enzyme, the reaction mixture (Tab. 
12) was incubated for 2 - 3 h or overnight. Afterwards, additional 1 μl of enzyme was 
supplemented for further 1 h. In case of double digestion the reaction could be carried out 
simultaneously using universal buffer (Tango) or buffer, which was suitable for both enzymes. 
If the enzymes required different buffers, digestion was performed consequently for each 
enzyme as follows: DNA was digested with one enzyme, the fragment was then isolated by 
agarose gel electrophoresis followed by agarose gel purification. Subsequently, procedure was 
repeated in the same way with the other restriction enzyme. 
 
Tab. 12 Preparative digestion reaction mixture  
Reagent  Volume (µl)  
10 x Restriction buffer  5  
BSA (optional)  0.5  
DNA  max. 10 μg  
Enzyme (dependent on star activity) 5  
ddH2O  Add to 50  
Final volume  50  
  
3.1.8 Ligation of DNA fragments 
Ligation reaction joins two ends of DNA strands and is driven by ligase enzyme. This reaction 
was used to insert DNA fragment into the plasmid vector. Therefore, the matching DNA ends 
of both fragment and vector, cleaved by restriction enzymes, were ligated using Ligate-ITTM 
Rapid Ligation Kit. This kit allows the reaction to occur within only 16 min. In order to perform 
ligation, an insert:vector ratio of 13:2 (v/v) was used.  
The reaction mixture (Tab. 13) was incubated for 8 min at RT, and afterwards placed for 8 min 
on ice. To check the success of ligation experiment and to estimate the number of self-ligated 
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plasmid, the reaction was set up along with ddH2O as a negative control instead of the insert 
fragment. High amounts of clones on the negative control plate after transformation into 
bacterial cells indicated non-successful ligation reaction. In order to increase the efficiency of 
transformation, ligation mixture was concentrated with the highest temperature in the vacuum 
centrifuge under 200 mbar for 10 min prior to transformation. The remaining DNA attached on 
the wall of tube after centrifugation was detached by pipetting the residual liquid. 
 
Tab. 13 Ligation reaction mixture 
Reagent Volume (µl) 
5 x Ligase buffer  4  
Plasmid vector  2  
Insert fragment  13  
Ligase  1  
Final volume  20  
 
3.1.9 Drop dialysis 
To purify and desalt the ligated DNA prior to bacterial transformation, drop dialysis was 
performed. For this purpose, nitrocellulose filters with shiny side up were placed for 5 min in a 
petri disch filled with ddH2O. The ligation mixture (about 20 µl) was carefully pipetted into the 
center of the filter preventing direct contact with ddH2O. After 30 min, dialyzed plasmid 
solution was carefully transferred from the filter to a new 1.5 ml Eppendorf tube. 
 
3.1.10   DNA isolation from bacteria 
 
3.1.10.1 Isolation of plasmid DNA by chloroform extraction (plasmid mini-preparation) 
Plasmid mini-preparation was used to isolate high-quality plasmid DNA for restriction 
digestion or sequencing. Single colonies, which appeared on agar plates after transformation 
were picked up and resuspended in 5 mL of LB-medium supplemented with the corresponding 
antibiotic, and left shaking overnight at 37°C. Next day, 5 μl of this solution were transferred 
to the agar plate, which has served as an inoculum for the further experiments. The rest of the 
bacteria solution was centrifuged at 4000 rpm for 10 min at RT. Then, the supernatant was 
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discarded and the pellet was resolved in 250 μl of Resuspension buffer (B1) and transferred to 
a new 1.5 mL Eppendorf tube. Next, the cells were lysed with 250 μl of Alkaline lyses buffer 
(B2) and strongly shaked. To neutralize the reaction 350 μl of Neutralization buffer (B3) were 
added and mixed through the inversion. Up five to six times was enough to see the precipitation 
of the proteins that indicated the neutralization of the mixture. Then, the samples were 
centrifuged at 13000 rpm for 10 min at RT. The supernatant was transferred in a new 1.5 mL 
Eppendorf tube and mixed with 500 μl of ice cold chlorophorm/isoamylalcohol (24:1) solution. 
The samples were centrifuged at 13000 rpm for 5 min at RT. The upper phase, which contains 
the plasmid DNA, was transferred to a new 1.5 mL Eppendorf tube. Afterwards, 650 μl of 
isopropanol (-20°C) were added and the mixture was spined at 13 000 rpm for 15 min at 4°C. 
The supernatant was discarded and the pellet washed with 700 μl of 70% ethanol (-20°C) at 13 
000 rpm for 7 min at 4°C. Then, the supernatant was removed and the tube with opened lid was 
placed on the heat block at 37°C shaking until the pellet became dry and clear. Finally, the 
pellet was resuspended in 50 μl of TE-buffer and DNA content was quantified photometrically.  
3.1.10.2 Isolation of plasmid DNA by solid extraction (plasmid midi-preparation) 
Plasmid midi-preparation extraction was used to isolate larger amounts of high-quality plasmid 
DNA from transformed E. coli cultures. Later the purified DNA was used for eukaryotic 
transfection. In this work, midi-prep was conducted with the help of the QIAGEN Plasmid Plus 
Midi Kit according to the manufacturer’s instructions.  
 
3.1.11 DNA sequencing 
DNA sequencing is a method, which allows sequencing of unknown DNA within the sites in 
which the sequence is known. The Sanger’s method, or dideoxy sequencing, or chain 
termination is based on the use of the dideoxy nucleotide triphosphates (ddNTP’s) in addition 
to the deoxy-nucleotide triphosphates (dNTP’s). The ddNTPs are fluorescently labeled and have 
different wavelengths of fluorescence and emission. The incorporation of ddNTPs, which 
contain a hydrogen group on the 3’ carbon instead of a hydroxyl group (OH), to the DNA strand 
prevent the addition of subsequent nucleotides. Thus, the termination of the DNA chain occurs 
resulting in the labeled ddNTP at the end of each DNA fragment with varying length. The newly 
produced and labeled DNA fragments are then denatured, and separated by size by capillary-
gel electrophoresis.  
Briefly, the reaction mixture (Tab. 14) was pipetted in a 384-well PCR plate. In this work, the 
sequencing reaction was performed using the BigDye® terminator v1.1 Sequencing Kit. The 
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primers used for sequencing are listed in the section 2.10, Tab. 6. The sequencing PCR was 
performed for 25 cycles under conditions as stated in the Tab. 15. 
 
Tab. 14 Sequencing PCR mixture 
Reagent Volume per sample (µl) 
DMSO  0.25  
Primer (10 μM)  0.5  
BigDye®  1  
ddH2O  2.25  
DNA (~300 μg/ml)  1  
Final volume  5  
 
Tab. 15 Sequencing PCR conditions 
Phase  Duration  Temperature  
Initial Denaturation  2 min  94°C  
Denaturation  15 sec  96°C  
Annealing  15 sec  56.5°C  
Elongation  4 min  60°C  
Final Elongation  7 min  60°C  
Cool down  for ever 8°C  
 
To get rid of any unincorporated dyes, excess primer and salts from the reaction buffers, the 
PCR product was purified using Sephadex prior to sequencing. Therefore, 35 mg of Sephadex 
G50 superfine were filled in the wells of a 96-well filter plate. Then 300 μl of ddH2O were 
added to each well and incubated for 3 h at RT. To remove the superfluous water the plate was 
spined at 650 x g for 5 min at RT. Further 150 μl of ddH2O were added to each well and 
incubated for another 30 min at RT. Again the superfluous water was removed by centrifugation 
under the same conditions (650 x g, 5 min, RT). Afterwards, 5 μl of the sequencing-PCR-
product were mixed with 35 μl of ddH2O and pipetted on Sephadex-containing filter plate and 
centrifuged under the same conditions (650 x g, 5 min, RT). Afterwards, the purified samples 
25 x 
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were sequenced using 3130xl Genetic Analyser. The sequencing data were analyzed with 
Staden Package software Version 4.0 and Clone Manager. 
 
3.1.12   Genotyping by single base primer extension method (SNaPshotTM) 
SNaPshotTM was used to determine the SNPs in genomic DNA. This method is based on the 
dideoxy single-base extension of an unlabeled oligonucleotide primer. A primer, which anneals 
immediately adjacent to the SNP is extended by one base using a fluorescently labeled ddNTP 
in the presence DNA polymerase, adding a single ddNTP to its 3’ end on the SNP position. The 
ddNTPs do not carry an OH-group on the 3'-terminus, which blocks the further elongation of 
DNA strand. SNaPshotTM reaction allows a direct visualization of the genotype of the SNP 
present in the expected region on a DNA fragment. Four different fluorescently labeled ddNTPs 
give a colored peak on a electropherogram after capillary electrophoresis when incorporated in 
the SNP region: Adenine - green (FS = dR6G); Cytosine -black (FS = dTAMRA
TM
); Guanine 
- blue (FS = dR110), Thymine - red (FS: dROX
TM
).  
The SNaPshotTM reaction in this work was performed as following: At first, the DNA fragment 
containing Arg25Pro polymorphism in TGFB1 was amplified. Therefore, the PCR reaction 
mixture was prepared (Tab. 16) and the region was amplified by PCR under the conditions 
stated in the Tab. 17. A primer pair used for this PCR is stated in the ection 2.10, Tab. 7. 
 
Tab. 16 PCR reaction mixture 
Reagent Volume per sample (µl) 
ddH2O, RNAse-free 6.33 
Buffer 1.1 
Q-solution  2.2  
dNTPs (10mM) 0.22 
Primer _for (pcDNA5-TGFB1-for) 0.05 
Primer_rev (TGFB1-human-rev) 0.05 
TopTag Polymerase 0.05 
DNA  1 
Final volume  11  
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Tab. 17 PCR reaction conditions 
Phase  Duration  Temperature  
Initial Denaturation  3 min  94°C  
Denaturation  30 sec  94°C  
Annealing  1 min  60.7°C  
Elongation  1 min  72°C  
Final Elongation  10 min  72°C  
Cool down  for ever 8°C  
 
Afterwards, the first purification step was performed. The PCR product was purified with 
Exonuclease I (ExoI) enzyme. ExoI was used to remove excess primers and any other single-
stranded DNA present in PCR products. Therefore, purification mixture (Tab. 18) was 
incubated for 3 h at 37°C, and then inactivated for 15 min at 80oC in the thermal cycler. 
 
Tab. 18 Reaction mixture for the first purification step  
Reagent   Volume (µl) 
10 x RX buffer  0.95 
Exo1 (20 U/µl) 0.35 
Fast-AP (1 U/µl) 1.7 
PCR product  4  
Final volume  7 
 
Then, the SNaPShot reaction using SNaPshot® kit was conducted. During preparation, the 
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Tab. 19 SNapShot PCR mixture 
Reagent  Volume per sample (μl)   
SNaPshot™-Master mix  0.5  
Primer mix (2-12μM)  0.5  
ddH2O  2  
Purified PCR-product  2  
Final volume  5  
 
Tab. 20 SNaPshot-PCR conditions 
Phase  Duration  Temperature  
Initial Denaturation  2 min  94°C  
Denaturation  10 sec  96°C  
Annealing  5 sec  50°C  
Elongation  30 sec  60°C  
Cool down  for ever  8°C  
 
Following SNaPshotTM reaction, the second purification step was performed. Shrimp alkaline 
phosphatase (SAP) was applied to dephosphorylate remaining dNTPs from the PCR product. 
Reaction mixture (Tab. 21) for the second purification step was incubated for 30 min at 37°C. 
 
Tab. 21 Reaction mixture for the second purification step 
Reagent  Volume (µl) 
SAP (1 U/μl)  5  
ExoI (10 U/μl)  0.2  
10 x SAP buffer  2  
PCR product  13  
Final volume  20 
 
26 x 
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Finally, 1 μl of the SNaPshot reaction mixture was added to 10 μL of the sequencing mixture 
(Tab. 22). For evaluation and determination of the exact length of the extended primers an 




Size Standard, was used. The reaction mixture was 
denatured for 5 min at 95°C, and then immediately placed on ice. Finally, the samples were 
visualized by electrophoreses on ABI 3730 and the data were analyzed with Gene Mapper v3.7 
software®.  
 
Tab. 22 Sequencing mixture 
Reagent  Volume per sample (µl) 
Formamid (Hi-DiTM Formamid)  10  
Gene ScanTM 120 LIZTM Size  0.05  
Sample  1 
Final volume 11.05 
 
 
3.2 RNA techniques 
 
3.2.1 RNA extraction 
To prevent quick degradation of RNA and RNAse contamination, sterile plastic ware and 
pipettes, which are dedicated only for RNA handling, were used. Before starting the procedure 
of RNA isolation, the working surface was cleaned with anti-RNase spray. For RNA extraction, 
about 1 x 106 cells were collected in falcone tube and centrifuged at 3500 x rpm for 3 min at 
RT. The supernatant was discarded and the pellet was rinsed with 500 μl of PBS buffer. Then, 
the pellet was lysed with 350 μl of RLT Plus buffer. The total RNA was isolated using the 
RNeasy Plus Mini Kit with QiaCube robot according to the recommended manufacturer’s 
protocol. After extraction RNA samples were placed immediately on ice, and then stored at 
- 80°C. 
 
3.2.2 RNA quantification 
The concentration of extracted RNA was measured photometrically on the maximum 
absorption of 260 nm. Three μl of the sample were pipetted into Implen-Nanodrope cuvette and 
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measured by BioPhotometer. To assess the purity of RNA, additionally to the extinction of 260 
nm, the absorbance ratio of 260/280 nm, which expresses the purity of RNA, was measured. 
The RNA samples with ratio above 1.9 were considered as pure and could be used for further 
experiments. 
 
3.2.3 Reverse transcription (RT) and cDNA synthesis 
In order to evaluate gene expression rate, total RNA was converted into complementary DNA 
(cDNA) via reverse transcription (RT) using SuperScript™ II reverse transcriptase. For setup 
of RT reaction, RNA-primer reaction mix was prepared. Therefore, 1 μg of mRNA was mixed 
with 1 µl of random primers (dN6). Random hexamer primers bind throughout the entire length 
of RNA and ensure reverse transcription of all RNA sequences due to their random structure. 
The samples were incubated at 70°C for 10 min to denature RNA secondary structure, and then 
placed on ice for 10 min to allow annealing of the primers. Afterwards, the RT-PCR mastermix 
(Tab. 23) was added to RNA-primer reaction mix and incubated at 42°C for 60 min. Finally, to 
adjust the concentration of the synthesized cDNA to 10 ng/μl, the samples were diluted with 
70 µl of ddH20 and stored at -20°C, 
 
Tab. 23 RT-PCR mastermix 
Reagent  Volume per reaction (µl) 
5 x Superscript RT buffer  6  
DTT (0,1 M)  3.5  
dNTPs (10 mM)  1   
RNase Inhib P/N (40 U/μl)  0.5  
Super Script™ II (200 U/μl)  0.25  
Final volume  11.25 
 
3.2.4 Quantitative real-time PCR (qRT-PCR) 
qRT-PCR is a method, which allows to monitor the cDNA amplification process in the real 
time. In qRT-PCR, the amount of PCR product is measured at each cycle via fluorescent dye. 
With each amplification cycle the increased fluorescencnt signal is directly proportional to the 
amount of generated amplicons (PCR product molecules). The lower the cycle number the 
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higher is the expression of the gene. The fewer the amount of specific cDNA was in the 
beginning, the more cycles of PCR was necessary to reach a threshold cycle (Ct) of a present 
DNA quantity (Higuchi et al. 1993). The Ct is the cycle number at which the fluorescent signal 
of the reaction crosses the threshold, which is the level of the signal that reflects a statistically 
significant increase over the calculated baseline signal. To normalize the expression rate of gene 
of interest, endogenous normalization gene (e.g. GAPDH, TBP etc.), so-called “housekeeping” 
gene, whose expression should be constant, was used. 
To quantify the expression of TGFB1 gene by qRT-PCR the following steps were performed: 
At first, 7 µl of qRT-PCR mastermix (Tab. 24) were pipetted in a 384-wells plate. Then, 3 µl 
of cDNA were added to the plate. The plate was covered with an optical clear foil and measured 
by TaqMan 7900HT under the conditions as stated in the Tab. 25. The TGFB1 expression was 
normalized to the GAPDH gene. The primers used for quantification of TGFB1 transcript 
variants and for the determination of GAPDH are listed in the section 2.10, Tab. 8. Finally, the 
results were analyzed using software SDS 2.1. 
 



















Reagent   Volume per sample (μl) 
qPCR Master mix  2  
Primer (1:10)  0.2  
ddH2O, RNA-se free  4.8  
cDNA (1:10)  3  
Final volume  10  
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Tab. 25 qPCR conditions. 
Phase Duration Temperature 
Initial denaturation 15 min 95°C 
Denaturation 15 sec 95°C 
Primer annealing 20 sec 60°C 
Elongation 1 min 72°C 
Melting curve  15 sec 95°C 
 15 sec 60°C 
 15 sec 95°C 
 
 
3.3 Protein techniques 
 
3.3.1 Protein extraction 
In order to isolate protein for Western blotting or ELISA, following steps were performed. The 
cells (5*105 – 1.5*106) were plated in the 6-well plate and incubated for 24-48 h at 37°C under 
5% CO2 and 95% humidity. Upon reaching approximately 80-90% confluence, the medium 
was replaced and the cells were irradiated with 5-25 Gy. Depending on the experiment, the cells 
were incubated for the next 24-72 h. Afterwards, the cells were carefully collected in 2 ml 
Eppendorf tube and sedimented at 1000 x g for 3 min at 4°C. Supernatant was transferred in a 
new Eppendorf tube and stored at -80°C. The pellet was washed with 500 µl PBS and 
centrifuged at 3000 x g for 3 min at 4°C. Then, PBS was discarded, the pellet was lysed with 
300 µl RIPA buffer and shortly vortexed at 1400 rpm. To ensure that the cells were broken, 
several freeze-thawing cycles in liquid nitrogen and warmed at 37°C were performed. Finally, 
prepared samples were stored at - 80°C. 
 
3.3.2 Quantification of protein by bicinchoninic acid (BCA) assay 
To quantify total protein in samples, BCA assay was used. This assay is performed in two steps. 
The first step is reduction of Cu2+ to Cu1+ by protein in an alkaline environment (the biuret 
reaction), which results in faint blue color, followed by second step - chelation and purple color 
40x  
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formation by bicinchoninic acid, that can be determined spectro-photometrically with 
maximum absorption at 562 nm. The intensity of the colored reaction product is in proportion 
to the amount of protein that can be determined by comparing its absorbance value to a standard 
curve.  
The BCA assay in this work was performed as follows: Working solution was prepared by 
mixing of BCA solution with cupric sulfate 4% with ration of 50:1. Ten µl of protein samples, 
diluted in 1:3 with RIPA buffer, were pipetted in duplicate in a single well of a transparent 96-
well plate. As a standard bovine serum albumin (BSA) was used. For this reason, the amounts 
of 0, 1, 5, 10, 15, 20, 25 μl of BSA stock solution (1mg/ml) were pipetted in duplicate. Then, 
200µl of BCA-cupric sulfate solution was added to each well.  
Then, the plate was incubated for 30 min at 37°C. Following incubation, protein absorption was 
measured at 570 nm wave length in Tecan Ultra Microplate reader. Protein concentration was 
determined by reference to a standard curve consisting of known concentration of the standard 
protein (BSA). 
 
3.3.3 Western blotting 
Western blotting is a technique to detect the presence and characterize a specific protein in a 
complex mixture extracted from cells by size separation during gel electrophoresis and then 
detection by a specifically directed antibody. 
3.3.3.1 SDS-polyacrylamid gel electrophoresis (SDS-PAGE) 
The purpose of SDS-PAGE is to separate proteins according to their size. Therefore, the protein 
was denatured by heating in gel loading buffer, which contains glycerol, a tracking dye 
(bromophenol blue) and a reducing agent like β-mercaptoethanol, SDS and DTT to reduce 
disulphide bonds. The polyacrylamide gel casts in two sections. The top section, where the 
wells are made and samples are loaded, is the stacking gel. The separation gel is the lower 
section, where the proteins are separated.  
Firstly, the separating gel was prepared. Therefore, the reagents were mixed together in the 
concentrations given in the Tab. 26. The gel was poured in the gel chamber Mighty Small SE 
Dual Gel Caster until 1.5 cm of the chamber top. The rest part of gel chamber was filled up 
with water. To get polymerize the gel was left for 30 min at room temperature (RT). Meanwhile 
the stacking gel was prepared. The water from the top of the chamber was discarded and the 
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stacking gel was poured on the top of the separation gel and left to polymerize for 30-40 min at 
RT. 
 
Tab. 26 SDS-PAGE gel recipe 
Reagent  4% stacking gel 12% separating gel 
ddH2O  1625 μl 2180 μl 
1.5 M Tris-HCl (pH 8,8)       - 1250 μl 
0.5 M Tris-HCl (pH 6,8)  625 μl    - 
10% (w/v) SDS  25 μl 50 μl 
40% (w/v) Acrylamid/Mix 37:5:1  250 μl 1500 μl 
10% APS  12.5 μl 25 μl 
TEMED  2.5 μl 2.5 μl 
 
3.3.3.2 Gel electrophoresis 
Once the gel was set, it was placed into the electrophoresis chamber Mighty Small II, which 
was filled with running buffer (1x) and allowed to pre-run at 12 mA for 30 min without samples. 
Meanwhile, the samples were denatured at 95°C for 5 min in the loading buffer (4x), then placed 
on ice for 5 min. After that, the samples were shortly spined and pipetted into the wells of gel. 
As a molecular weight marker, SeeBlue®Plus2 Prestained Standard was used. Afterwards, the 
gel was run at 12 mA until the loaded samples reached the border of separation gel, and then at 
25 mA until the samples run out of the gel.  
3.3.3.3 Blotting 
Following the gel electrophoresis, gel was transferred on the blotting membrane. In this work, 
a semidry transfer method was used. The gel and blotting membrane (polyvinylidene difluoride 
(PVDF) were assembled into a sandwich along with several sheets of filter paper. Before 
assembly, the PVDF membrane had to be activated by methanol for 30 sec, and then washed 
with ddH2O. Then, the washed membrane was soaked in the transfer buffer for 10 min shaking 
at RT. Six thick and two thin Whatman filter papers were also soaked in transfer buffer for 
10 min shaking at RT. The transfer buffer for electroblotting was used to help proteins bind to 
the blot. The gel sandwich arranged on the electroblotting apparatus. The air bubbles were 
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removed by pushing gently across the surface rolling with a pipette. Blotting was performed at 
45 mA (per gel) for1-1.5 h at RT.  
3.3.3.4  Confirmation of the transfer  
Once the blotting step has been completed, the success of the blotting was evaluated by staining 
the blotting membrane with Ponceau S solution. Therefore, the membrane was incubated for 
5 min in Ponceau S solution. Following incubation, the mebane was washed three times for 
5 min with ddH20. 
3.3.3.5  Blocking 
After blotting, to prevent non-specifically binding of antibody to the membrane, the blot 
containing the transferred protein bands was incubated with Roti®-Block (1:10 dilution) 
shaking for 1 h at RT. After blocking, the blot was rinsed three times in 20 mL of wash buffer 
(TBST), every time soaking for 5 min. 
3.3.3.6 Antibody incubation 
Following washing procedure, the blot was incubated with primary antibody diluted in 5 mL of 
TBST buffer (1x) shaking overnight at 4°C. Next day, the membrane was washed tree times for 
5 min with 20ml of TBST buffer and incubated with horse radisch peroxidase (HRP) conjugated 
secondary antibody, diluted in 10 ml of TBST, for 1 hour shaking at RT. Afterwards, the blot 
was washed again three times for 5 min with 20mL of TBST buffer. Antibodies used in this 
work are listed in the section 2.4. 
3.3.3.7 Normalization 
In order to compare target protein expression levels between several different samples on the 
same blot, the "house-keeping gene" GAPDH was used as a loading control to normalize the 
data. Probing with GAPDH antibody was carried out along with the target antibody. Therefore, 
the sample was loaded on the gel in duplicate - for target protein of interest as well as for 
GAPDH detection. 
3.3.3.8 Detection with substrate 
In the final step of the immunodetection procedure, the HRP in the secondary antibody was 
detected by the enhanced chemiluminescent (ECL) substrate solution. Therefore, the membrane 
was incubated for 2 - 3 min with 500 µl of Luminol/Enhancer and 500 µl Peroxide Solution 
from the SuperSignal® West Pico Kit. The chemiluminescent images were captured using 
VersaDoc-3000 and quantified using Quantity One software. 
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3.3.4 Immunocytochemistry 
Immunocytochemical study aimed to assess the expression and localization of TGFβ1 protein 
in the cells. The procedure was performed using primary antibody for target protein and 
fluorochrome conjugated secondary antibody. 
First, to avoid clumps or aggregates of the cells, cell suspension (5x105cells/1mL) was pipetted 
through a 40 micron cell strainer. Then, the cells were centrifuged at 1400 rpm for 3 min and 
washed with 1 mL of PBS. Afterwards, the cells were seeded in poly-D-lysine coated 12 well-
plate and incubated at 37°C until they had reached 80-90% confluence. As next, culture medium 
(DMEM, 10 %FBS, 1% Pen/Strep, Hygromycin B (100 µg/mL)) was removed and the wells 
were rinsed once with 1 mL of PBS buffer. The cells were fixed with 500 μl/well of Histofix 4% 
and incubated for 20 min at RT. Afterwards, the cells were permeabilized with                 
0.5%  Triton X - 100 for 5 min and again washed one time with 1 mL of PBS buffer. To block 
unspecific binding of the antibodies, the cells were incubated with 1 mL of Roti-block solution 
(1:10 dilution) shaking for 60 min at RT. Afterwards the primary monoclonal antibody (1:1000)  
diluted in 500 µl of PBS per well was added and incubated shaking for 60 min at RT. Then, 
each well was washed twice with 1 mL of PBS. After washing steps, cells were incubated with 
Alexa Fluor 488 secondary antibody (1:400 in PBS) and DAPI (1:1000) shaking in the dark for 
60 min at RT. Antibodies used in this work are listed in the section 2.4.  
Following incubation, the cells were washed three times with 1 mL of PBS, soaking for 3 min 
each time. Finally, to prevent cells from drying 500 µl of PBS were added to each well. The 
cell were visualized by immunofluorescent microscopy. The plates with fixed cells could be 
stored for several weeks in the dark at 4°C.  
 
3.3.5 Enzyme Linked Immunosorbent Assay (ELISA) 
To quantify the amount of active and latent TGFβ1 protein in the culture supernatant and cell 
lysates, sandwich-ELISA was performed. This quantitative enzyme immunoassay is based on 
indirect immobilization of the antigen by capture antibody and indirect detection by enzym-
labelled secondary antibody. 
In two independent ELISA assays, the expression rate of LAP versus the active TGFβ1 was 
measured. To determine the expression level of active TGFβ1, the Human/Mouse TGFB1 (2nd 
generation) ELISA Ready-Set-Go! Kit according to the manufacture’s instruction was used. 
This kit allowed quantification of mature/active form of TGFβ1 as well as free active TGFβ1 
present without acidification. When acidification was required, the samples were incubated 
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with 1N HCl for 10 min at RT, and then, neutralized with 1N NaOH. Free active TGFβ1 in the 
samples was measured without acid treatment. 
The LAP was quantified using the Human LAP (TGF-beta1) ELISA Ready-SET-Go! Kit 
according to the manufacture’s instruction. LAP ELISA kit enables measurement of LAP in 
non-dissociated samples and does not require sample acidification and neutralization. In each 
assay the samples as well as the standards were run in duplicate. To determine the concentration 
of TGFβ1 and LAP, the mean values of the samples were compared to the standard curve and 
normalized to the total protein concentration. 
 
3.4 Working with bacteria 
 
3.4.1 Growth conditions and long-term storage of bacteria 
In this study, bacterial transformation was conducted with the electrocompetent bacteria strains 
One Shot® TOP10 Electrocomp™ E. coli and DH10B. Bacterial strains were cultured both in 
liquid and solid media. Liquid bacterial clones were incubated with appropriate antibiotic either 
5 mL in 15 mL falcon tubes (for plasmid mini-preparation, see section 3.1.10.1) or 100 mL in 
500 mL glass bottles (used for plasmid midi-preparation, see section 3.1.10.2) while shaking 
on K2 260 basic-shaker at 250 rpm at 37°C overnight. The agar plates with bacterial clones 
could be stored at 4°C for about one month sealed with parafilm. 
For long time the bacterial cultures were stored at -80°C, mixed 1:1 with 50% glycerol solution 
in a 1.5  mL Eppendorf tube. 
 
3.4.2 Bacterial transformation  
Bacterial transformation in this work was performed via electroporation or by the heat shock 
method. 
Transformation via electroporation is used to transfer plasmid DNA into E.coli by applying a 
short high-voltage electric field pulse (~2,500 volts/cm). The process results in smalls cracks 
in the membrane and enables DNA to enter bacteria. Briefly, 10 µl of E. coli TOP 10 bacteria, 
diluted in 30 µl of ddH2O, were mixed with the 2 – 3 µl of the dialyzed plasmid DNA (after 
drop dyalisis, see section 3.1.9) and transferred in a pre-cooled 2 mm electroporation cuvette. 
The electroporation was performed using Gene Pulser II with the settings 2.5 kV, 25 μF and 
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200 Ω for about five milliseconds. Then, the electroporated cells were immediately diluted with 
800 μl of warm LB- or S.O.C. media and incubated at 37°C for 1 h to allow expression of the 
antibiotic resistance gene. Subsequently 50 – 200 μl of the transformed bacteria were spread on 
the pre-warmed agar plates supplemented with appropriate antibiotic and incubate at 37°C 
overnight.  
Transformation via heat shock allows plasmid DNA to enter the bacterial cell via plasma 
membrane pores, which are formed by sudden increase in temperature. In this work for 
transformation through heat shock DH10B bacteria was used. Briefly, 50 µl of bacteria were 
pipetted in 1.5 mL Eppendorf tube and placed on ice for 30 min. Then, 25 ng of plasmid DNA 
were added to the Eppendorf tube and incubated for next 30 min on ice. When time was up, the 
bacteria and plasmid mixture were placed in a water bath for 90 sec at 42°C, and then 
immediately on ice for five min. Afterwards, the mixture was transferred to a new 1.5 mL 
Eppendorf tube containing 800 µl of prewarmed S.O.C. media and left shaking at 37°C for 1 h. 
Subsequently, 100-200 µl of transformed bacteria were added to agar plates supplemented with 
appropriate antibiotic and incubate overnight at 37°C. 
 
 
3.5 Mammalian cell culturing 
 
3.5.1  Used cell lines and culturing conditions 
All cell lines were kept in the incubator at 37°C under 5% CO2 and 95% humidity. The culture 
media was pre-warmed at 37°C in a water bath before applied to the cells. Cells splitting 
frequency was dependent on the proliferation rate of the cell line and on the purpose of the 
planned experiment. To calculate the number of cells needed for experiments, Neubauer-cell 
chamber was used. Therefore, 20 µl of cell suspension was mixed 1:1 with Trypan Blue. Then, 
10 µl of prepared solution were pipetted to the Neubauer-cell chamber. The living cells were 
counted and the required cell concentration per well was calculated. 
Flp-In™ T-REx 293cell line is a cell line derived from the human embryonic kidney 293 
(HEK 293) cells. The Flp-In™ T-REx 293cell line, containing Flp Recombination Target (FRT) 
integrated into a specific site on the genome, enables stable transfection and integration of a 
gene of interest using the Flp-InTM system. The cells were cultured in DMEM medium 
supplemented with 10% FBS and 1% Penicillin/Streptomycin and 0,1% Zeocin. The cells were 
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trypsinized to assure the homogeneous distribution of the single cell. Therefore, 3 mL of trypsin 
were added to the culture flask and incubated for approximately 3 min at 37°C. To deactivate 
trypsin, a 6 mL of culture media were added. Then, the cells were collected in 50 mL falcon 
tube and centrifuged at 300 x g for 3 min. The supernatant was removed and the cell pellet was 
resuspended in fresh media. The cells were counted and necessary amount of the cells was 
plated. 
Human skin fibroblasts (kindly provided by Departments of Dermatology and General Surgery 
of University Medical Center Göttingen) were used for transient transfections, followed by 
immunochemistry. The cells were cultured in DMEM medium containing 10% FBS and 1% 
Penicillin/Streptomycin. The fibroblasts are adherent cells, therefore to detach and to prepare 
them for splitting or for an experiment trypsinization was required. Three ml of trypsin was 
added to the culture flask and incubated for 3-5 min at 37°C. For trypsin neutralization, three 
ml of culture media was added. The cells were collected in 50 ml falcon tubes and centrifuged 
at 500 x g for five min. The supernatant was removed and the cell pellet was resuspended in 
fresh media. The cells were counted and the necessary amount of cells was plated. 
NIH 3T3 mouse embryonic fibroblast cell line is a standard fibroblast cell line, which in this 
study was used for transient transfections, followed by Western blotting and immunostaining 
analysis. 3T3 means that the cells were transferred (T) every 3 days and plated 3 x 106 cells per 
plate. The cells were kindly provided by Naim Kittana (Institute of Pharmacology, University 
Medical Center Göttingen). NIH 3T3 fibroblasts were cultured in DMEM media containing 
10% FCS, 1% Penicillin/Streptomycin, 4.5g/L glucose and L-glutamine. To split the cells or to 
prepare them for the experiments, the cells were treated with trypsin as described above.  
  
3.5.2 Freezing cultured cells  
For future experiments and long-term maintenance, cells were stored in liquid nitrogen. For 
cryopreservation only low-passaged cells were used. After reaching 80% confluency, the cells 
were harvested and transferred to 50 mL falcon tube and pelleted by centrifugation at 300 x g 
for 3  min at RT. The supernatant was discarded and the pellet was resolved in 6.8 mL of ice-
cold freezing solution containing 90% of pure FCS and 10% of sterile DMSO. All steps were 
performed on ice. Resuspended cells were transferred into 1.8 mL cryotubes and placed for 1 h 
on ice. Then, the cryotubes were transferred to -80°C for one week. For further storage, the 
cells were transferred to the liquid nitrogen storage container (about -170oC).  
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3.5.3 Thawing cultured cells  
Cryotubes containing frozen cells were removed from the liquid nitrogen storage container and 
rapidly thawed in a hand until the outer surface of the cells ice block started to melt. Then, the 
cells were immediately transferred to the 50 mL falcon tube containing 10 mL of pre-warmed 
culture media and centrifuged at 300 x g for 3 min at RT. The supernatant was discarded and 
the pellet was gently resuspended in 10 ml of pre-warmed medium (medium type according to 
the culture recommendations of the specific cell line), transferred to a 25 cm2 culture flask and 
cultured under standard condition. After several passages, the cells were transferred to 75 cm2 
culture flask. 
 
3.6 Mammalian cell transfection 
Transfection is the procedure of transporting foreign nucleic acids into mammalian cells by 
using chemical, lipid or physical based methods. In this study, the cells were transfected 
transiently and stably by lipofection.  
 
3.6.1 Transient transfection 
Transiently transfected cells express the gene of interest for a limited period of time (24-48h), 
but this gene is not integrated into the genome.  
Depending on the cell line and approach (Western blotting or immunocytochemical analysis), 
2 -5 x 105 cells were plated in a 12 well plate and incubated at 37°C and 5% CO2 to reach 70-
80% confluence. In this study, pcDNA5.1/TGFB1_FLAG plasmid was transiently transfected 
into the cells using FuGene 6® transfection reagent. The procedure was performed as follows: 
Firstly, 100 μl of pure DMEM media were mixed with 12 μl of FuGene 6 transfection reagent 
in 1.5 mL Eppendorf tube and incubated for 5 min at RT. Then, 2 μg of plasmid DNA was 
added to the reaction mix and incubated for 15 min at RT. In the meantime, the cells were rinsed 
once with 1 mL of PBS. After that, 1 mL of the DMEM medium containing 1% 
Penicillin/Streptomycin antibiotics was added to each well and 112 µl /well of reaction mix was 
pipetted. The transfected cells were incubated at 37°C for 24-48 hours and afterwards lysed 
with RIPA buffer (for Western blotting) or fixed and permeabilized (for 
immunocytochemistry). 
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3.6.2 Stable transfection  
In contrast to transient transfection, stable transfection allows integration of the gene of interest 
into the genome of mammalian cells. Chromosomal integration of the transfected DNA 
construct enables long-term studying of gene expression in the transfected cells. The introduced 
DNA construct has a marker gene (antibiotic resistance gene) which allows to select stably 
transfected cells. When applying selective antibiotic to the cells, the cells that were not 
transfected or were transiently transfected die, and those that express the antibiotic resistance 
gene at sufficient levels survive. 
In this work, stable transfection was performed using Flp-In™ T-REx HEK 293 cell line. This 
cell line contains pFRT/lacZeo plasmid with integrated lacZ-Zeocin™ fusion gene and Flp-
Recombination Target (FRT) site. FRT is inserted downstream of the ATG initiation codon of 
the lacZ-Zeocin™ fusion gene and is a target site for Flp recombinase. Next, an expression 
plasmid pcDNA5.1 with inserted gene of interest TGFB1 was co-transfected. Expression of the 
gene of interest is under the control of the human cytomegalovirus (CMV) promoter. The 
pcDNA5.1 plasmid also contains the hygromycin resistance gene with FRT site. Beyond 
pFRT/lacZeo and pcDNA5.1/TGFB1 plasmids, Flp recombinase expression plasmid pOG44 
was co-transfected. The Flp recombinase catalyzes a homologous recombination event between 
the FRT sites in the Flp-In™ T-REx HEK 293 cell line and the pcDNA5.1/TGFB1 plasmid.  
In order to transfect pcDNA5.1/TGFB1 construct, the following steps were performed: The 
cells were plated at 9 x 105 per well in 6-well plate and incubated overnight at 37°C. After 
reaching approximately 80-85% confluence, the cells were ready for transfection. At first, 
transfection mix was prepared. Therefore, 100 μl of pure DMEM medium was mixed with 12 μl 
of FuGene 6 transfection reagent per well and incubated for 5 min at RT. Afterwards, 3.6 μg of 
pOG44 plasmid and 0.4 μg of pcDNA5.1/TGFB1 plasmid were added to the transfection 
reagent and incubated for 15 min at RT. Meanwhile, the cells were rinsed twice with DMEM 
medium supplemented with 10% FCS and 1.9 mL of the same media were added to each well. 
Then, 112 µl of transfection mix/well were added to the cells and incubated for 48 h. 
Afterwards, the cells were transferred to the 92 mm petri dish with 9 mL of DMEM medium 
supplemented with 10% FBS serum and 1% Penicillin/Streptomycin antibiotics. Following 
overnight culture the old medium was discarded and 9 mL of DMEM medium supplemented 
with 10% FBS serum and 1% Penicillin/Streptomycin, as well as the screening antibiotic 
Hygromycin B (300 μg/ml), was added. Ten days following transfection, untransfected cells 
died and successfully transfected cells have generated colonies. Each single colony was picked 
up and transferred into a single well of a 12-well plate, then to 6-well plate, and then to 25 cm2, 
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and finally to 75 cm2 culture flask. In further culturing steps the Hygromycin B concentration 
was reduced up to 100 μg/mL in order to increase the cells growth. Afterwards, the stable 
transfected cells were characterized on genome level by PCR, on mRNA level by qRT-PCR 
and protein level by Western blotting and ELISA.  
 
3.6.2.1 Validation of chromosomal integration of the constructs in pcDNA 5.1 plasmid 
After stable cell lines were generated as previously described (see section 3.6.2) genomic DNA 
was isolated (see section 3.1.4). Then, the correct chromosomal integration of the gene of 
interest as well as the hygromycin resistance gene was checked. We have performed two 
independent PCRs using two pairs of primers complementary to the hygromycin resistance gene 
and to the TGFB1 gene. 
First integration-specific PCR was performed in order to verify integration of the hygromycin 
resistance gene in the chromosomal DNA of the stable transfected T-REX HEK293 cells. The 
PCR was conducted in a reaction mixture (Tab. 27) with forward primer “PSV40” and reverse 
primer “Hyg” (primer sequence see in section 2.10, Tab. 5) under conditions stated in Tab. 28. 
The forward primer annealed in the SV40 promoter of the pFRT/lacZeo plasmid. Reverse 
primer annealed to the hygromycin resistance region of the pcDNA5.1 plasmid.  
 
Tab. 27 Mixture for confirmatory PCR for hygromycin resistance gene integration. 
Reagent Volume per sample (µl) 
10 x buffer  2  
dNTPs (2 mM)  2  
MgSO4 (25 mM)  0.8 
Q-Solution  4  
Forward primer PSV40 (10 nM)  0.5 
Reverse primer Hyg (10 nM)  0. 5  
Template DNA (300 ng/μl)  2  
KOD HotStart Polymerase (1.0 U/μl)  0.5  
ddH20  9.7  
Final volume 22 
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Tab. 28 Conditions for confirmatory PCR for hygromycin resistance gene integration 
Phase  Duration  Temperature  
Initial denaturation  2 min  95°C  
Denaturation  30 sec  95°C  
Annealing  30 sec  68°C  
Elongation  1 min 30 sec  72°C  
Final elongation  10 min  72°C  
for ever  8°C  
 
 
In order to confirm the correct chromosomally integration of the TGFB1 gene, second PCR was 
performed using PCMV and LacZ primers (primers sequence see in the section 2.10, Tab. 5). 
This PCR (Tab. 30) amplified the region between the downstream part of PCMV promoter and 
the upstream part of lacZ/Zeocin resistance region which contains TGFB1 cDNA. The reaction 
mixture was prepared as denoted in the Tab. 29. 
 
Tab. 29 Mixture for confirmatory PCR for gene of interest 
Reagent Volume per sample (µl) 
10 x ExpandLong buffer  2.8 
dNTPs (2 mM)  4.5 
MgSO4 (25 mM)  1  
Q-Solution  5.6  
Forward primer PCMV (10 nM)  0. 5  
Reverse primer LacZ (10 nM)  0. 5  
Template DNA (300 ng/μl)  3  
ExpandLong Polymerase Mix  0.3  
ddH20  9.8  
Final volume  28  
 
35 x 
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Tab. 30 Conditions for confirmatory PCR for gene of interest 
PCR-Condition Phase  Duration  Temperature  
Initial denaturation  2 min  94°C  
Denaturation  30 sec  96°C  
Annealing  30 sec  64.4°C  
Elongation  3 min 30 sec  70°C  
Final elongation  10 min  68°C  
for ever   8°C 
 
3.7 Statistical analysis  
Descriptive analysis refers to visualization of data distribution. In my thesis, different groups 
according to the allelic configuration and treatment procedures were illustrated by boxplots, 
which apply also for non-parametrically distributed data. The relationship between two 
continuous variables, i.e. the pH and the TGFβ1 activation, was depicted by two-dimensional 
plots, displaying mean values of independent experimental repetitions with the respective 
standard deviations. 
Analytical procedures used in this work comprise the Mann-Whitney and the Shapiro-Wilk test 
as well as linear regression analysis. For the data visualized by boxplots testing for statistical 
differences between two independent groups (e.g. Arg25 versus Pro25, radiation versus control) 
was performed by the non-parametric Mann-Whitney U test. For two dimensional plots, fitting 
of a regression line was indicated by the coefficient of determination. Impact of more than one 
independent parameters (i.e. pH, allelic configuration) on a dependent variable (i.e. amounts of 
active TGFβ1) was assessed by linear regression analysis. Prior to linear regression analysis, 
data distribution was evaluated for compatibility with normal distribution by Shapiro-Wilk test 
(a p-value > 0.01 was considered as sufficient to apply the parametric linear regression 
analysis). In general, p-values of less than 0.05 were regarded as statistically significant. The 
statistical analyses were carried out using SPSS statistical software package (version 12.0) and 
Microsoft Excel.  
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4 Results 
To pinpoint the functional role of the Arg25Pro polymorphism, may it be related to 
expression, intracellular processing, secretion or activation of TGFβ1, we started with 
generation of allele-specific constructs. 
 
4.1 Generation and confirmation of stably transfected TGFB1 
constructs  
The two alleles of the Arg25Pro polymorphism had to be cloned in a human model cell 
line in order to stably express the two referring proteins. At first, genetic constructs were 
generated prior to transfection. Upon transfection, the correct genomic integration was 
ascertained by two independent PCRs. Primer extension method was employed to confirm 
the allelic identities of Arg25 and Pro25-bearing constructs. Expression of transfected 
TGFB1 was assessed by qRT-PCR and Western blotting.  
 
4.1.1 Generation of stably transfected cell lines expressing TGFB1 
For subsequent functional analyses, the first aim was to introduce the entire TGFB1 coding 
region for both the Arg25 and Pro25 variant in the mammalian expression vector 
pcDNA5.1 containing a FRT site for later stable genomic integration. Starting with the 
bacterial pOTB7 plasmid, in which the TGFB1 coding region containing Arg25 was 
supplied, as a first step site-directed mutagenesis was carried out to generate Pro25 (see 
section 3.1.6). Second, the TGFB1 coding regions were transferred from pOTB7 into 
pcDNA5.1 plasmids by cutting with HindIII and XhoI restriction enzymes and subsequent 
ligation (Fig. 4, for methodological details see sections 3.1.8 and 3.1.8). Ligated plasmids 
were then transformed into One Shot® TOP10 E. coli strain via electroporation (see section 
3.4.2), and purified by plasmid mini-preparation (see section 3.1.10.1). The correctness of 
TGFB1 insertion into pcDNA5.1 plasmid was checked by analytical digestion (see section 
3.1.7.1) and sequencing including evidence of either the Arg25 and Pro25 allele (see 
section 3.1.11). 
The generated constructs were intended to stably transfect into human T-REx HEK 293 
cells using the Flp-In system (see section 3.6.2). 
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Fig. 4 Scheme of cloning of TGFB1 into the expression vector pcDNA5.1.                             
In the upper part, the two vectors pOTB7 and pcDNA5.1 (with the Flip-in Recombinant Target, FRT) are 
displayed. After digestion with the indicated restriction enzymes, ligation was performed resulting in the 
plasmid shown at the bottom of the figure. 
 
 
4.1.2 Verification of correct genomic integration 
Successfully transfected cells were screened for hygromycin resistance by antibiotic 
selection. Positive clones were then cultured as described previously (see section 3.6.2). 
Next, successful genomic insertion of the pcDNA5.1/TGFB1 constructs was confirmed by 
two integration-specific PCRs. The first PCR (labeled as “PCR 1” in Fig. 5) amplifies the 
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region from the pSV40 promoter to the hygromycin resistance gene. The product of the 
expected length (614 bp) revealed the correct integration of all six pcDNA5.1/TGFB1 
constructs (three each for Arg25 and Pro25) into the HEK cells genome (Fig. 6.).  
 




Fig. 6 Integration-specific PCR confirming the correct integration of the hygromycin resistance gene 
in the genome of T-REx HEK 293 cells.                              
Transfected constructs containing pcDNA5.1 with TGFB1 (three clones each for Arg25 and Pro25) and 
pcDNA5.1 without TGFB1 insert (second column next to the 1 kb ladder). Non-transfected T-REx HEK 293 
cells (column 3) served as a negative control. The desired product length of the fragment was about 614 bp. 
 
The second PCR was done to prove the correct genomic integration of the TGFB1 gene 
into the HEK 293 host cells (Fig. 7). Therefore, the region between the downstream part of 
PCMV promoter and the upstream part of the lacZ-Zeocin resistance region was amplified. 
As shown in the Fig. 8, the expected fragment length of 2594 bp could be verified for five 
of the six transfected TGFB1-containing clones  
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Fig. 8 Integration-specific PCR confirming the correct integration of the plasmid constructs in the 
genome of T-REx HEK293 cells.                                         
Samples positioning is identical to Fig. 6. The desired product length of the fragment of interest was 2594 bp. 
For the vector without TGFB1 insert this product accounts for 1424 bp. 
 
Presence of the two alleles in the transfected host cells was confirmed by SNaPShotTM 
reaction (see section 3.1.12). This reaction was preceded by a PCR with a primer pair (see 
Tab. 7), which was specific for the pcDNA5.1/TGFB1 construct; thus, the respective host 
TGFB1 genomic region was not amplified. The subsequent SNaPShotTM confirmed the 
allelic identities at the Arg25Pro polymorphism in the transfected cells. 
 
4.1.3 mRNA expression of transfected TGFB1 
Using qRT-PCR, mRNA expression of the transfected TGFB1 coding region in the 
HEK 293 cells was quantified. The obtained results showed that TGFB1 mRNA expression 
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level in cells carrying the wild-type Arg25 or variant Pro25 was about 12 to 19-fold higher 
compared to empty vector-transfected control (Fig. 9). Furthermore, when comparing the 
three clones with Arg25 with those of Pro25 there was no significant differences (p = 0.4 
according to t-test). Based on the above-mentioned genetic analysis and the qRT-PCR, one 
clone each for the Arg25 wild type and one for the Pro25 variant was selected for further 
experiments (highlighted by arrows in the Fig. 9). 
 
Fig. 9 Expression rate of TGFB1 in the stably transfected T-Rex HEK 293 cells.                                                                             
The raw TGFB1 relative transcript levels were normalized to GAPDH expression and this ratio was referred 
to the empty vector pcDNA5.1. The red arrows indicate the clones chosen for subsequent functional analyses. 
 
4.1.4 TGFß1 protein expression in transfected cells 
To evaluate TGFβ1 protein expression Western blotting was performed. Immunoblotting 
with an antibody against TGFβ1 showed a strong band with about 50 kD reflecting 
intracellular monomeric LAP-TGFβ1 protein. The analysis for the supernatant 
demonstrated mature TGFβ1 protein at 12.5 kDa (monomer). These patterns were detected 
for both the constructs with the Arg25 and the Pro25 allele. Regarding supernatant, the 
amount of secreted mature TGFβ1 appeared much higher for the Pro-transfected constructs 
than for those with Arg25 as confirmed by three independent repetitions. 
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Fig. 10 Western blot of TGFβ1 protein in transfected T-REx HEK 293 cells.                 
The top panel shows the lysate (with GAPDH as reference), the bottom the supernatant. Untransfected cell 
were used as a control. The presented qualitative pattern is representative for three independent immunoblots. 
Input of equal protein amounts was ascertained by prior assessment of total protein by BCA assay. 
 
In summary, assessment of correct genomic integration, mRNA transcription and 
translation into protein demonstrated proper cellular models overexpressing either Arg25 
or Pro25 of the TGFβ1 precursor protein suitable for further functional analyses. 
 
4.2 Localization of TGFβ1 protein 
To gain better insights into localization of TGFβ1 protein in the cell, we generated 
constructs for Arg25 and Pro25 with a FLAG tag as an indicator of TGFβ1 localization. 
FLAG-protein is an eight amino acids epitope tag (DYKDDDDK), which allows better 
detection of expressed proteins (Terpe 2003). Two approaches for positional insertion of 
the FLAG tag were chosen. First, directly behind the first methionine in the signal peptide 
of the TGFβ1 precursor due to the vicinity of the index polymorphism Arg25Pro. Second, 
at the N-terminus of the mature TGFβ1 protein, to address the question whether trafficking 
of mature TGFβ1 is affected by Arg25Pro. Both cloning approaches were carried out for 
Arg25 and Pro25. 
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4.2.1 Generation and transient transfection of TGFB1 with FLAG tag behind 
methionine (MetFLAG) 
To place a FLAG tag into the signal peptide, 24 nucleotides coding for FLAG were inserted 
in the common open reading frame sequence immediately after the three initial nucleotides 
coding for methionine.  
Starting from the two previously generated plasmids of pcDNA5.1 with either Arg25 or 
Pro25 (see section 4.1.1) a PCR was set up comprising the entire open reading frame of 
TGFB1 with a nucleotide sequence coding for FLAG inserted in the forward primer (for 
primers see Tab. 3). The PCR products were digested with HindIII and XhoI restriction 
enzymes and ligated into pcDNA5.1 plasmid harboring the same restriction sites. The 
correct insertion of FLAG in the generated constructs was proven by sequencing (see 
section 3.1.11).  
The constructs were transiently transfected (see section 3.6.1) into HEK 293 cells using 
FuGENE®6 transfection reagent. Following 24-48 h incubation in serum-free defined 
conditions, the cells were lysed for Western blotting or fixed for immunocytochemistry. 
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Fig. 11 Scheme for insertion of FLAG tag behind methionine in signal peptide of TGFβ1.                       
A fragment containing TGFB1 coding region and FLAG coding sequence was inserted behind methionine in 
signal peptide and amplified by PCR. After digestion with the indicated restriction enzymes ligation was 
performed resulting in the plasmid shown at the bottom of the figure. The steps were performed for Arg25, 
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4.2.2 Generation and transient transfection of TGFB1 with FLAG tag at 
N- terminus of mature TGFß1 
In the second approach, the FLAG tag was inserted at the 5ꞌ-end of the nucleotide sequence 
coding for mature TGFβ1. To minimize the possibility of reduced cleavage efficiency we 
reiterate the nucleotides for the first five amino acids of mature TGFβ1 directly before the 
FLAG tag as described formerly (Chubet and Brizzard 1996).  
A sequence of 189 bps (Tab. 4) was commercially synthesized and cloned into the pEX-A 
vector with restriction sites for BamHI and BstXI. This sequence contains the 24 
nucleotides coding for FLAG flanked on either side by the 15 nucleotides coding for the 
first five amino acids of mature TGFβ1 as well as additional sequence parts of the C-
terminal LAP (5ꞌ-side) and further parts of the N-terminal mature TGFβ1. Next, the 
obtained pEX-A was transferred into DH10B bacteria by heat shock to amplify the plasmid 
amount (see section 3.4.2). Bacteria were harvested and plasmids were isolated by mini-
preparation (see section 3.1.10.1). Isolated plasmids were simultaneously digested by 
BstXI and BamHI. The previously generated pcDNA5.1/TGFB1 plasmids for either Arg25 
or Pro25 were digested with the same enzymes. Finally, the digested samples were 
visualized by agarose gel electrophoresis (see section 3.1.2). The desired fragments were 
cut out from the gel, purified (see section 3.1.3) and ligated (see section 3.1.8). The steps 
performed for preparation of the constructs are illustrated in the Fig. 12. Preparation and 
further investigations of these generated constructs were performed in collaboration with 
Naim Kittana (Institute of Pharmacology, University Medical Center Göttingen).  
The constructs for Arg25 and Pro25 with FLAG tag at the N-terminus of mature TGFβ1 
were transiently transfected (see section 3.6.1) into the HEK 293, NIH 3T3 cells and human 
skin fibroblast (see section 3.5.1). Following 24-48 h incubation in serum-free defined 
conditions, the cells were lysed for Western blotting or fixed for immunocytochemistry.  
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Fig. 12 Scheme for insertion of FLAG at the N-terminal site of mature TGFβ1.                                   
A fragment containing C-terminal parts of LAP and N-terminal parts of mature TGFβ1 with FLAG in 
between was used to replace corresponding regions in previously generated plasmids of pcDNA5.1 with 
TGFβ1 (one for Arg25 and one for Pro25, see Fig. 4).  
 
4.2.3 Western blotting of transiently transfected TGFB1 with FLAG tags  
Constructs with FLAG tag either following the first methionine or at the N-terminus of 
mature TGFβ1, each for Arg25 and Pro25, were transfected into HEK 293 cells. Expression 
of the respective protein was checked by Western blotting with antibodies directed against 
either TGFβ1 or FLAG.  
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For the constructs with the FLAG tag inserted following the first methionine, probing with 
anti-FLAG did not show any band neither for cell lysates nor for cell culture media. 
However, when probing with antibody against TGFβ1 a strong band with about 55 kD 
reflecting intracellular monomeric LAP-TGFβ1 was observed (Fig. 13). 
This protein size corresponds to what was seen for the stably transfected T-REx HEK 293 
cell (Fig. 10). However, in culture media no TGFβ1 was detected. 
 
Fig. 13 Western blot for the translated product of FLAG tag behind methionine.                
As host cells HEK 293 cells were used. Lysate and cell culture media were probed by FLAG and TGFβ1 
antibodies separately (image only shows probing with TGFβ1 antibody, no bands were obtained for FLAG 
antibody). Untransfected cell were used as a control. GAPDH was employed as reference for intracellular 
protein levels. 
 
For the constructs with the FLAG tag inserted at the N-terminus of mature TGFβ1 probing 
with FLAG antibody demonstrated strong signals with HEK 293 and NIH 3T3 cells as host 
(Fig. 14) with protein sizes corresponding to what was seen for the stably transfected 
T - REx HEK 293 cell (Fig. 10). In the cell lysate, a signal of ~55 kDa for TGFβ1 protein 
in precursor state was obtained. In culture media of HEK 293 cells, a signal of ~13 kDa for 
the mature TGFβ1 was observed. This was true for both alleles of the Arg25Pro 
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Fig. 14 Western blot for the translated product of FLAG tag at the N-terminus of mature TGFβ1.                 
As host cells HEK 293 (A) or NIH 3T3 (B) cells were used. For both cell lines, lysate and cell culture media 
were probed separately. Untransfected cell were used as a control. GAPDH was employed as reference for 
intracellular protein levels. 
 
4.2.4 Immunocytochemical analysis 
To determine TGFβ1 protein localization in the transiently transfected HEK 293, NIH 3T3 
cells as well as in human skin fibroblast immunocytochemical assay was performed. The 
cells expressing FLAG tag at the N-terminus of the sequence corresponding to mature 
TGFβ1 as well as untransfected cells as control were immunostained as described before 
(see section 3.3.4) and visualized by immunofluorescence microscopy. The obtained 
immunofluorescence images (Fig. 15) showed perinuclear localization of the protein 
translated from the transfected constructs in all three cell types investigated. This 
localization suggests association with endoplasmatic reticulum or Golgi apparatus. These 
signals were specific for transfected cell lines and were not present in sham-transfected 
cells.  
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Fig. 15 Immunocytochemistry images indicating localization of the translated product with FLAG tag 
at the N-terminus of mature TGFβ1.              
As host cells HEK 293 cells (A), NIH 3T3 (B) cells and primary human skin fibroblasts (C) were used. For all 
three cell types, immunocytochemistry by FLAG antibody was carried out for transfected constructs containing 
Arg25, Pro25 or for untransfected host cells. In the first row (A), TGFβ1 with FLAG is indicated by red and 
nucleus by blue (DAPI). In the second row (B), TGFβ1 with FLAG is indicated by red, nucleus by blue (DAPI), 
and ER and Golgi by green staining. In the third row (C), TGFβ1 with FLAG is indicated by green, nucleus by 
blue (DAPI), and ER and Golgi by red staining. 
 
4.3 Arg25Pro polymorphism: Effects on expression 
Several mechanisms how allelic variants may exert biological functions are conceivable 
(see section 1.3). First, it was investigated whether Arg25Pro affects expression of the 
encoded protein. As modulation of mRNA expression was ruled out previously (Schirmer 
et al. 2012) possible alterations on translation were analyzed here using the generated stably 
transfected cell lines. Therefore, intracellular contents of LAP and of active TGFβ1 were 
repeatedly examined for both variants. 
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Amounts of LAP and active TGFβ1 did not significantly differ on baseline level between 
cells transfected with either Arg25 or Pro25 (Fig. 16). Upon irradiation with 1 x 25 Gy a 
trend toward decreased LAP expression in presence of Pro25 was observed. Intracellularly, 
contents of LAP representative for the inactive LAP-TGFβ1 were about 50,000-fold higher 
than those of active TGFβ1. 
 
 
Fig. 16 Arg25Pro in regard to intracellular expression of LAP (A) and mature (B) TGFβ1.                   
T-REx HEK 293 cells were plated at 1.25 x 106 per well and cultured for 24 h at 37°C. Then, the cells were 
irradiated or sham-irradiated followed by further incubation of 24 h. Cell lysates were quantified either for 
LAP (A) or TGFβ1 (B) by ELISA and referred to total protein contents as ascertained by BCA assay with 
each sample determined in duplicate. Regarding panel B, the amounts of active TGFβ1 were assayed by 
ELISA, i.e. without prior acidification. The shown data refer to eight independent experiments for each allele. 
The cells were lysed with RIPA buffer containing protease and phosphatase inhibitors. Statistical difference 
between the two alleles was assessed by Mann-Whitney U test.  
 
4.4 Arg25Pro polymorphism: Impact on secretion 
The effect of Arg25Pro on secretion of LAP-TGFβ1 was determined in the generated stably 
transfected cells. Taking into account that active TGFβ1 may be incompletely dissociated 
after acidification or be re-associated with LAP after neutralization (Arestrom et al. 2012), 
measurement of LAP secretion was considered as proxy for TGFβ1 precursor.  
The amount of secreted LAP protein was significantly higher for Pro25 than for Arg25 
under baseline conditions, i.e. cell culturing without any specific treatment. Actually, for 
cells transfected with Pro25 secretion of LAP was two times higher than for Arg25. 
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Moreover, upon irradiation with one shot of 25 Gy the amount of secreted LAP remained 
significantly higher for the cells carrying the Pro25 variant (Fig. 17 A) whereby irradiation 
resulted in decreased LAP secretion for both alleles.  
When considering the ratio of secreted versus intracellular LAP it clearly turned out that a 
much higher fraction of LAP is secreted in cells with Pro25 (Fig. 17 B). This was true for 
baseline conditions as well as upon irradiation.  
 
 
Fig. 17 Impact of Arg25Pro on secretion of LAP.                      
Two experimental conditions, i.e. sham-irradiation and a single shot with 25 Gy each with eight independent 
replications, were investigated both for the Arg25- and the Pro25-transfected T-REx HEK 293 cells. Panel A 
displays the amounts of LAP secreted from the cells into the culture media. Panel B shows the ratio of LAP 
found in the cell culture supernatant with respect to intracellular LAP (for the latter see Fig. 16). Experimental 
conditions and statistical analysis were identical to those described in Fig. 16. 
 
4.5 Arg25Pro polymorphism: Impact on activation of TGFβ1 
Acidification represents one major mechanism for activation of TGFβ1 from its latent 
complex (1.3.4). The hypothesis was tested whether the Arg25Pro polymorphism may 
modulate pH-dependent activation of TGFβ1. 
In culture supernatants of cells transfected with either Arg25 or Pro25 a linear curve fit for 
TGFβ1 in dependence on the pH value was obtained. Under physiological conditions, 
(pH ~ 7.4) similarly low amounts of activated TGFβ1 were observed for both alleles (Fig. 
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18 A). Increasing acidification suggests more TGFβ1 activated in presence of the Pro25 in 
comparison to the Arg25 allele. In linear regression with adjustment for pH this allelic 
effect turned out statistically significant (p = 0.0004 for Fig. 18 A). As higher secretion of 
LAP in case of Pro25 was demonstrated (Fig. 17) the obtained data for active TGFβ1 were 
normalized to secreted LAP amount. Upon normalization to LAP, a steeper slope of TGFβ1 
activation with increasing acidification was noticed in culture supernatants derived from 
constructs with Arg25 compared with Pro25 (Fig. 18 B, p = 0.000009). The latter suggests 
TGFβ1 produced with Arg25 could easier be activated, however, not compensating 



















Fig. 18 pH-dependent activation of TGFβ1 in relation to total protein (A) and LAP (B).             
Culturing of T-Rex HEK 293 cells was identical to that described in Fig. 17. The cell culture supernatants 
were treated with acid (1 N HCl) to adjust to pH-values of 7.4, 6.5, 5.5, 4, 3.5, 2.5, and 1.5. Following 10 min 
incubation at RT, the samples were neutralized (by 1 N NaOH with the same volumes as used for 
acidification) and TGFβ1 was immediately quantified by ELISA. The graph depicts the amount of TGFβ1 
relative to the total protein content in dependence on the pH value. The shown data refer to three independent 
experiments of which the respective mean values with standard deviation are depicted. Within each 
experiment, each sample was assayed in duplicate. The interpolated regression line is based on a presumed 
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4.6 Arg25Pro polymorphism: Impact on simulated RCT 
In order to evaluate if the observed impact of Arg25Pro polymorphism on LAP secretion 
(Fig. 17) can also apply in clinical situation, RCT in stably transfected T-REx HEK 293 
cells was simulated. Therefore, the cells carrying either Arg25 or Pro25 were subjected to 
3 x 5Gy irradiation in presence of 5-FU (3 µM). 
Here, under baseline conditions, a statistically significant difference for the amounts of 
secreted LAP protein from cells transfected with either Arg25 or Pro25 was not observed. 
However, it should be noted that the cells in this experimental series were cultured for a 
total of 120 h until harvesting in contrast to 48 h for which Arg25 and Pro25 differed 
substantially (see Fig. 17). Upon 120 h without any cytotoxic treatment acidification of the 
culturing media and cell overgrowth as manually inspected by microscopy was observed. 
Whereas this problem was barely avoidable when simulating RCT for several days it could 
explain absence of statistical difference between the two variants. In fact, when the cells 
were treated with 5-FU and irradiated the effect of Pro25 again was elucidated. With the 
latter treatment, cell proliferation was lowered resulting in less cell overgrowing in the 
culturing plates. 
Regarding active TGFβ1 no effect of Arg25Pro was observed using the identical samples 
neither under baseline nor RCT conditions (data not shown). 
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Fig. 19 Impact of Arg25Pro on secretion of LAP when simulating RCT.                  
Stably transfected T-REx HEK 293 cells were plated at 5 x 105 per well and cultured for a total time of 120 h 
at 37°C. First, upon plating cells were allowed to grow for 48 h before fresh medium was supplied. For the 
wells simulating RCT, 5-FU was added to a final concentration of 3 µM. Following 1 h incubation, the cells 
were irradiated with one shot of 5 Gy or sham-irradiated, respectively. The irradiation was repeated two more 
times every 24 h. After the last irradiation the cells were incubated for additional 24h, culture supernatants 
and cell pellets were then harvested. Quantification of LAP was performed by ELISA and referred to total 
protein contents as ascertained by BCA assay with each sample determined in duplicate. The shown data 
refer to six independent experimental series for each allele and each condition. Statistical difference between 
the two alleles was assessed by Mann-Whitney U test.  
 
In a linear regression analysis the effect of the Arg25Pro polymorphism was adjusted for 
irradiation and 5-FU exposure in accordance with the clinical situation. This analysis 
corroborated the relevance of Arg25Pro and demonstrated no major impact of RCT 
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Tab. 31 Linear regression analysis for the fraction of secreted LAP.                          
The impact of Arg25Pro was adjusted for RCT. The data refer to those used in the Fig. 19. This analysis was 
applicable as compatibility of data with normal distribution was given (all p ≥ 0.01 according to Shapiro-
Wilk test).  
Variable Standardized coefficient (95% confidence interval) p value 
Arg25Pro 0.51 (0.25-0.76) 0.0002 
3x5Gy -0.12 (-0.37-0.14) 0.4 
3µM 5-FU 0.16 (-0.09-0.42) 0.2 
 
 
4.7 Prediction of signal peptide cleavage 
Modifications in signal peptide sequences can potentially change the cleavage site position 
resulting in inefficient signal peptide processing (Palzkill et al. 1994), and thus, may affect 
the TGFβ1 synthesis (Faria et al. 2007, Jiang et al. 2002). 
In order to predict the cleavage site in dependence on both variants of the Arg25Pro 
polymorphism, the SignalP tool (version 4.1), which is available in the internet 
(http://www.cbs.dtu.dk/services/SignalP/), was applied. A markedly distinct pattern for 
cleavage sites in presence of Arg25 or Pro25 was predicted (Fig. 20). In case of Arg25, the 
cleavage site position appeared equivocal with two major hits suggested between either the 
codons Glu24/Arg25 or the codons Glu29/Leu30 (Fig. 20A). In contrast, when Pro25 is 
present one distinct cleavage site position between the codons Glu29 and Leu30 was 
presumed (Fig. 20B). 
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Fig. 20 In silico prediction of signal peptide cleavage site of the TGFβ1 precursor.                         
The upper panel (A) displays cleavage site prediction for Arg25, the lower (B) for Pro25. The x-axis exhibits 
the amino acid sequence with the respective codon position indicated. The y-axis represents score values 
ranging from 0 (minimal) to 1.0 (maximum). The C-score estimates the most likely position of the first amino 
acid in the mature protein (position +1). The S-score is a signal peptide score, which recognizes signal peptide 
and is high at all positions before the cleavage site. The Y-score denotes the combined cleavage site score 
and is calculated by a geometric average of the C-score and the slope of the S-score. Maximal Y-score 
represents the predicted cleavage site (Emanuelsson et al. 2007). The predicted cleavage sites are marked in 
both graphs by arrows in black. 
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5 Discussion 
The starting point of the present work was based on a clinical finding which showed a 
reproducible impact of the Arg25Pro polymorphisms in the TGFB1 gene on acute toxicity in 
patients with rectal cancer receiving N-RCT (Schirmer et al. 2012). All carriers of the Pro25 
variant experienced high grade acute organ toxicity (HGAOT). The purpose of this work was 
to investigate possible functional roles of the Pro25 in comparison to the Arg25 allele and by 
that to explain molecular mechanisms behind the observed clinical association.  
Due to the location of Arg25Pro in the signal peptide the hypotheses of affecting translation, 
secretion or activation of TGFβ1 were analyzed by means of stably transfected T-REX 
HEK 293 cells overexpressing either Arg25 or Pro25. Whereas no effect of Arg25Pro on 
intracellular protein expression of LAP-TGFβ1 under baseline conditions was observed (Fig. 
16) a major alteration in secretion rate of the inactive TGFβ1 in complex with LAP was detected 
(Fig. 17). A minor modification toward sensitivity of activating by acidification was also 
noticed. 
 
5.1 Pro25 variant results in higher secretion rate 
A major effect on the secretion rate of the inactive LAP-TGFβ1 complex was noted being about 
two times higher for stably transfected cells with Pro25 than with Arg25. This was consistently 
seen in all conducted experimental series with a plenty of independent replications performed 
over several months. An artificial difference between cells with either Arg25 or Pro25 
constructs is much improbable for several reasons: First, clones were selected with comparable 
intracellular mRNA (Fig. 9) and protein (Fig. 10) expression. Intracellularly, the amounts of 
TGFβ1 and LAP should be much similar since co-translated within the same open reading 
frame. Second, both intracellular and extracellular amounts of TGFβ1-LAP complex were 
normalized to total protein contents. Third and most important, for each experimental series 
culture supernatants and cell lysates were matched and thus the ratio of extracellular to 
intracellular LAP reflecting the secretion rate controls for confounding by differential 
transfection efficacy. 
The Arg25Pro polymorphism was barely investigated with respect to functionality in literature 
so far. One report addressed effects of Arg25Pro and another frequent polymorphism in close 
vicinity, i.e. Leu10Pro, on expression and secretion of TGFβ1 using allele-specific genetic 
constructs (Mohren and Weiskirchen 2009). They stated Pro25 and Pro10 might be related to 
5 Discussion                                      76 
reduced TGFβ1 expression rather than altering its secretion. This is contradictory to my 
findings. Technical discrepancies may account for that. Whereas in the cited publication 
transient transfection was applied, I used stable transfection. The latter one allows 
measurements over extended time frames and transfection efficacy could better be controlled. 
Interestingly, a former report (Dunning et al. 2003) also using transient transfection indicated 
an increased secretion rate for the Pro10 allele in sharp contrast to the study by Mohren and 
Weiskirchen (2009). In my experimental series, transiently transfected and expressed TGFβ1 
did also not reveal a distinct intracellular distribution pattern dependent on Arg25Pro as 
ascertained by Western blotting (Fig. 13, Fig. 14) and immunocytochemistry (Fig. 15). These 
discrepant findings highlight the necessity of transfection control, which is much less 
achievable in case of transient transfection also due to rapid dynamics. Furthermore, the host 
cells used by Mohren and Weiskirchen (2009) were different from the T-REx HEK 293 cells 
which I used, therefore cell type-specific effects could not completely be excluded. Another 
study investigated a potential impact of Arg25Pro on the amount of secreted TGFβ1 in isolated 
human leucocytes (Awad et al. 1998). However, the samples sizes were pretty low (25 carriers 
of Arg25/Arg25 and 9 of Arg25/Pro25) for the purpose to prove or to deny an association. 
Furthermore, in that study no control for other potentially confounding genetic variation was 
performed. According to data comprising a sample size twice as high as that from Awad et al. 
1998) published from our working group no significant modulation of TGFβ1 plasma 
concentrations by Arg25Pro was observed (Schirmer et al. 2011). 
The two-fold higher fraction of secreted LAP-TGFβ1 in presence of Pro25 in contrast to Arg25 
was true both under baseline conditions as well as when simulating RCT (Fig. 17B). As this 
secretion rate was not altered by any of the administered RCT simulations (i.e. 1 x 25Gy, 
3 x 8.3Gy, 3 x 5Gy with and without 5-FU used as radiosensitizer), the secretory mechanisms 
may not much be affected by RCT. As RCT is a major activator of latent TGFβ1 it could be 
assumed that higher secretion rates of TGFβ1 might result in extended levels of active TGFβ1 
when patients are exposed to RCT. Besides affecting the rate of secretion it is also conceivable 
that Arg25Pro might change the composition of the secreted protein (by altering the cleavage 
site of the signal peptide), which may affect subsequent activation of latent TGFβ1. 
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5.2 Increased sensitivity toward pH activation of TGFβ1 in constructs 
with Arg25 
TGFβ1 is secreted by most cultured cells as a part of the latent complex and low pH was 
suggested as one of the possible mechanisms for TGFβ1 activation from its latent complex 
(Lyons et al. 1988). Mild acid treatment (pH 4.5) activates 20-30% of latent TGFβ1, whereby 
extreme pH (1.5) results in significant activation of TGFβ1 (Lyons et al. 1988). Thus, stepwise 
increases of acidification were used to test the propensity of the latent TGFβ1 complex toward 
activation. In case of Pro25 more active TGFβ1 was detected (Fig. 18A). However, 
acidification-induced increase in relative amounts of active TGFβ1 normalized to secreted LAP 
was more pronounced for Arg25 (Fig. 18B). The latter effect might in part compensate for the 
enhanced secretion rate in case of Pro25 (Fig. 17), however, still leaving higher active TGFβ1 
amounts under acidifying conditions. In this respect, Fig. 18A could be regarded as a combined 
result of opposing effects of Pro25 on secretion rate (Fig. 17) and sensitivity of the latent 
complex toward activation (Fig. 18B). In summary, these data indicate higher concentrations 
of active TGFβ1 in inflamed and acidified tissue in patients harboring the Pro25 allele. In 
leucocytes, which represent a major source of TGFβ1, the primary control of TGFβ1 function, 
is not on the expression level but on secretion and activation in line with the effects I observed 
for the Pro25 in contrast to the Arg25 allele (Assoian et al. 1987, Grotendorst et al. 1989). 
 
5.3 Arg25Pro polymorphism may affect cleavage of signal peptide 
The Arg25Pro polymorphism is located within the 29 amino acid-comprising signal peptide of 
the TGFβ1 precursor. As stated in detail in the Introduction section (1.3.2), the signal peptide 
directs the TGFβ1 precursor to the rough ER (Gentry et al. 1988, ten Dijke and Arthur 2007). 
During or immediately after translocation of the protein to the ER lumen cleavage of the signal 
peptide is catalyzed by signal peptidases (Andrews et al. 1988 (Lemberg and Martoglio 2002). 
Following cleavage, the signal peptide initially accumulates in the ER membrane, and later 
degrades (Zimmermann 2009). 
Signal peptide sequences comprise usually 16-30 amino acids whereby three distinct regions 
could be distinguished: a positively charged N-terminal region, a central hydrophobic core, and 
a polar C-terminal region (Randall and Hardy 1989, Zimmermann 2009). The N-amino-
terminal region consists of 5-8 amino acids, and is represented by the presence of basic residues. 
The central hydrophobic core contains 8-12 nonpolar amino acids and has a tendency to from 
alpha-helices. The C-terminal region (or cleavage region), which is usually 6 amino acids long, 
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comprises a signal peptidase recognition site (Jain et al. 1994). Amino acids like proline, 
glycine or serine are often found in the cleavage region. If any substitution or deletion is present 
in this region cleavage may occur less efficiently (Jain et al. 1994). Proper cleavage requires 
small and neutral residues at -3 and -1 relative to the cleavage site (Nielsen et al. 1997). In this 
regard, the Arg25Pro polymorphism in the TGFβ1 precursor corresponding to position -5 may 
modulate rather than abolish cleavage in accordance with the bioinformatic analysis (Fig. 20). 
It represents an exchange of arginine (polar positively charged basic amino acid) by proline 
(non-polar hydrophobic amino acid).  
 
5.4 Mechanistic suggestion for clinically observed radiotoxicity 
Based on my findings, increased acute radiotoxicity in presence of Pro25 reported by Schirmer 
et al. (2012) might be explained by enhanced secretion of LAP-TGFβ1. This higher secretion 
may lead to higher concentrations of TGFβ1 upon activation (see schematically drawn in  
Fig. 21). Even in case of Arg25 the LAP-TGFβ1 complex appeared to be more sensitive to 
activation, there was still a net effect of more active TGFβ1 upon acidification for Pro25 due to 
the two-fold higher secretion rate of the LAP-TGFβ1 complex. Upon activating stimuli, these 
higher amounts of active TGFβ1 in case of Pro25 might explain the observed clinical 
association. Such stimuli typically present during radiotherapy comprise radiation (Barcellos-
Hoff and Dix 1996) or inflammation accompanied by tissue acidification (Lyons et al. 1988).  
TGFβ1 is known to act as a major orchestrator of inflammatory conditions (Sanjabi et al. 2009). 
At inflammatory sites, TGFβ1 produced particulary by leucocytes and acting both in 
autocrine/paracrine manner a well as a chemoattracant for invading leucocytes and other cells 
participating in immune response (Letterio and Roberts 1998). Though TGFβ1 over years was 
prevalently regarded as an immunosuppressive cytokine there is as well increasing evidence 
that this pleiotropic cytokine can, under certain circumstances, promote inflammatory reactions 
(Wan and Flavell 2008). Intriguingly, when the canonical TGFβ1 pathway was inhibited by a 
small molecule acute radiation-provoked inflammatory reactions were mitigated in mice 
(Flechsig et al. 2012). Thus, this finding supports the hypothesis that under conditions of 
radiotherapy TGFβ1 might act as an enhancer of radiotoxic side-effects. Regarding humans, 
clinical trials assessing antibodies, anti-sense nucleotides and small molecules targeting TGFβ 
in malignancies were launched (Buijs et al. 2012). As far as I am aware, no substance for TGFβ 
targeting has been approved for clinical use yet (July 2014).  
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Mechanistically, high concentrations of TGFβ1 in inflammatory leasions stimulate monocytes 
to synthesize and secrete other growth factors like TNFα and IL-1. Involvement of fibroblasts 
and endothelial cells in inflammatory response contributes to initiation of cell proliferation and 
matrix synthesis. Thus, repeating application of stimuli activating TGFβ1 like fractionated 
radiotherapy over weeks might result in sustained liberation of growth-promoting and matrix-
inducing factors (Wahl et al. 1989). Morover, in presence of IL-6 TGFβ1 initiates the 
differentiation of T helper 17 (Th17) cells (Sanjabi et al. 2009). High amounts of IL-17 
produuced by Th17 cells can induce further inflammation by activating matrix 
metalloproteases, which can cause collagen degradation. Moreover, IL17 promotes neutrophils 
recruitment further assisting in pro-inflammatory responses (Veldhoen and Stockinger 2006).  
Interestingly, when testing expression of proteins mechanistically linked to fibrosis only 
increased TGFβ1 was also associated with acute kidney allograft recection upon transplantation 
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5.5 Limitations  
When considering the results of my work, certain limitations are needed to be taken into 
account.  
First, the role of LTBPs, which constitute optional binding proteins for LAP-TGFβ1, was not 
considered. LTPBs, albeit not essential, enhance proper assembly and secretion of LAP-TGFβ1. 
It is thus conceivable that LTBPs might modulate the observed effect of the Arg25Pro 
polymorphism on LAP-TGFβ1 secretion. 
Moreover, with respect to the clinical settings, treatment courses which patients receive over 
weeks could not be reflected by the experimental procedure though two different applications 
of radiation, i.e. 1 x 25 Gy or 3 x 5 Gy, were employed. A more extended experimental 
procedure was not easily feasible. With the purpose of minimizing interventions during 
incubation, longer incubation times were not possible due to overgrowing of non-irradiated 
cells. Thus, with the obtained data an extrapolation on the clinical setting used at the University 
Medicine in Göttingen for treatment of rectal cancer, i.e. 28 x1.8 Gy, is limited. 
Finally, the effects observed in stably transfected T-REx HEK 293 might be cell context-
specific, and thus possibly not easily transferable to other cell types. Assessment of the 
relevance of the Arg25Pro polymorphism in cells regarded as crucial for normal tissue reactions 
of radiotherapy, e.g. immune cells and fibroblasts, is pending. In particular, the ability of a 
model cell line to reflect processes in tissues with heterogeneous cell types is limited.  
 
5.6 Perspectives  
Based on the findings from my thesis, further investigations could be directed to extend 
mechanistic and clinical views regarding the relevance of the Arg25Pro polymorphism.  
The observed alteration in LAP-TGFβ1 secretion rate may be due to different signal peptide 
cleavage for Arg25 in contrast to Pro25. Therefore, the hypothesis suggested by in silico 
analysis (Fig. 20) could be experimentally proven by mass spectrometry of LAP-TGFβ1 
secreted by the generated cell constructs.  
Mice models engineered as knock-in for either Arg25 or Pro25 might allow comprehensive 
investigations in the context of a macroorganism. Interestingly, human and mouse LAP-TGFβ1 
have an identical length of 390 amino acid residues with 90% sequence identity. Regarding the 
signal peptide, only one out of 29 residues differs between these two species (leucine at codon 
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16 on human and proline in mouse). Besides to study entire tissue reactions in animal models, 
they also will allow to simulate an entire course of radiotherapy administered to patients. 
Clinically, further trials in prospective fashion should be launched to confirm the actual 
relevance of the Arg25Pro polymorphism. If confirmed, this polymorphism might become a 
biomarker for individual treatment stratification. For the patients who carry the Pro25 risk allele 
and necessitate the intended radiotherapy intensified care might be offered. This might include 
prophylactic procedures (like anti-inflammatory drugs) during RCT to decrease treatment-
related side effects. If deeper insights into processes related to the signal peptide cleavage will 
be available specific pharmacological interventions might become conceivable. Monoclonal 
TGFβ antibodies are already tested in clinical trials to prevent tumor metastasis. It remains to 
be evaluated if they apply to control better radiation-induced side effects by blocking TGFβ 
receptors thereby counteracting excessive secretion of LAP-TGFβ1 in patients with Pro25.  
Beyond the relation to radiotherapy, the Arg25Pro polymorphism might be of relevance also 
for other clinical entities where inflammatory processes occur, e.g. kidney fibrosis, liver 
cirrhosis or heart failure. Thus, this polymorphism could be checked as a potential biomarker 
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In radiochemotherapy administered for rectal cancer, all patients harboring the Pro25 allele in 
the signal peptide of TGFβ1 experienced a higher grade of acute treatment toxicity. Pro25 
features an allelic frequency of about 10% in the Caucasian population and replaces an arginine 
residue. The functional role of this Arg25Pro polymorphism is still not clarified. Therefore, the 
aim of my work was to determine the possible molecular mechanisms driving the reported 
clinical association. 
In order to investigate allele-specific effects of the Arg25Pro polymorphism stable trasnfection 
to overexpress either Arg25 or Pro25 was carried out. As host cells, T-REx HEK 293 cells were 
used. The transfected cells were characterized on genome level by specific PCRs, for mRNA 
expression by quantitative real time PCR, and for protein expression by Western blotting. 
Transient transfection with FLAG tag-containing TGFβ1 constructs was employed to localize 
subcellular TGFβ1 distribution visualized by immunocytochemistry. Quantitative expression 
was determined by ELISA directed to either an epitope of the LAP or the mature TGFβ1 both 
for intracellular and secreted amounts. Clinically administered radiochemotherapy was 
simulated on the stably transfected cells. 
A major effect of the Arg25Pro polymorphism was observed on the secretion rate of the inactive 
LAP-TGFβ1 complex. Under baseline conditions without irradiation, the stably transfected 
cells carrying Pro25 secreted two times higher amounts of LAP-TGFβ1 than the cells harboring 
Arg25 as assesd by ELISA (p=0.0002). This increased level of secreted TGFβ1 in presence of 
Pro25 was confirmed by Western blotting. Radiation did not result in changes of the fraction of 
secreted LAP-TGFβ1 compared to non-irradiated cells. Intracellular amounts of LAP-TGFβ1 
and active TGFβ1 were not affected by the Arg25Pro polymorphism. FLAG epitope staining 
upon transient transfection indicated perinuclear localization of TGFβ1 suggesting its 
association with ER or Golgi apparatus. There were no apparent distribution distinctions 
dependent on the Arg25Pro polymorphism. 
Stepwise acidification was used to test the hypothesis whether the Arg25Pro polymorphism 
may modulate activation of TGFβ1. Increasing proton concentrations revealed more activated 
TGFβ1 normalized to the inactive LAP-TGFβ1 in case of Arg25 in comparison with Pro25. 
This allelic effect was still evident when adjusted for pH in linear regression analysis. Though 
secreted TGFβ1 from Arg25-containing constructs appeared more sensitive toward activation, 
there was a net effect of more active TGFβ1 by pH-dependent activation for Pro25. This was 
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due to substantially higher amounts of secreted and thus potentially activatable LAP-TGFβ1 
molecules.  
Altered secretion rate in dependence on the Arg25Pro polymorphism might be due to distinct 
cleavage sites patterns. Thus, prediction of the cleavages site position was conducted in silico. 
For Pro25 one cleavage site position between the codons Glu29/Leu30 and for Arg25 two sites, 
i.e. at Glu24/Arg25 and at Glu29/Leu30, were predicted.  
In conclusion, the data of my thesis indicate that an increased secretion rate in case of Pro25 
might contribute to the clinically reported association of this allele with acute radiotoxicity. 
Distinct patterns of signal peptide cleavage for the Arg25 and the Pro25 allele may lead to 
higher secretion rates of LAP-TGFβ1. As ionizing radiation and tissue acidification are major 
activators of LAP-TGFβ1, increased active TGFβ1 in irradiated tissue might result for carriers 
of Pro25 possibly explaining the radiotherapy-related toxicity. Pharmacological interference to 
target elevated TGFβ1 secretion, activation or subsequent signaling might offer strategies to 
prevent patients at particular risk for radiation injuries. Such approaches might also be 
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